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To understand the regulation of the pathophysiological processes, such as inflammation, 
thrombosis and atherosclerosis, it is very important to characterize the interactions between 
circulating cells and which molecules that contributes to and promote these interactions. As a 
part of this, the role of eicosanoids in cell-cell interactions in whole blood ex vivo and isolated 
blood cells are investigated. In this study, various inhibitors were used to regulate the amount 
of prostaglandins (and leukotrienes) and how these eicosanoids affect the activity- and 
expression level of tissue factor (TF), cytokines, enzymes, and receptors involved in the 
intercellular communication. 
 
Before the inhibition study, time course experiments revealed that the incubation times 
between 1.5 h and 2 h was sufficient for further study of the parameters under investigation.  
In the inhibition study, whole blood samples were preincubated with different eicosanoid 
inhibitors, and then stimulated with LPS for ninety minutes prior to TF activity measurement 
and real-time PCR analysis of cytokine gene expressions.  
 
Aspirin did not significantly enhance the lipopolysaccharide (LPS)-induced TF activity in 
whole blood, however a trend for enhance induction was indicated. Prostaglandin inhibitors 
enhanced the LPS-induced TF activity compared to a vehicle control, with significant effect 
for the microsomal prostaglandin E synthase (mPGES) inhibitor MF63. A dual 
cyclooxygenase-2/ 5-lipoxygenase (COX-2/ 5-LOX) inhibitor was used to investigate what 
happened if the leukotriene pathways were blocked in parallel with COX-2. And although not 
significant, an inhibitory effect of monocyte TF activity was seen for the weakest and 
strongest dose. 
 
To measure the mRNA expression of the cytokines tumor necrosis factor (TNF-α), interleukin 
1β (IL-1β), IL-8 and monocyte chemotactic protein-1 (MCP-1), real-time PCR analysis was 
performed. Aspirin was found to generally increase the gene expression of these cytokines. 
Moreover, significant enhancement of the IL-8 mRNA expression was found for all doses of 
aspirin, varying from 67% to 78% enhancement for 20 μM and 200 μM, respectively. For IL-
1β and TNF-α mRNA expression was increased by 86% (2 μM) and 36% (200 μM), 
respectively. Like aspirin, the selective cyclooxygenase-1 (COX-1) inhibitor SC-560, 
increased mRNA expression of all cytokines. The most pronounced effects were observed for 
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IL-8 and IL-1β. The MCP-1 mRNA expression level was greatly enhanced, however due to 
testing a low number of individuals for this cytokine, the effect was not significant.  
The enhancement of IL-8 expression was also seen after addition of the selective COX-2 
inhibitor, CAY10404. With the exception of IL-8, the highest dose of COX-2 inhibitor caused 
an insignificant reduction in mRNA expression for all cytokines. The lowest dose of 
prostaglandin synthesis inhibitor CAY10526 resulted into most pronounced mRNA 
expression for TNF-α, IL-1β and IL-8. However, the inhibitor did not significantly enhance 
the LPS-induced TF mRNA expression. Samples with mPGES-1 inhibitor (MF63) showed a 
bi-phased expression for nearly all the genes. However, the middle dose of the inhibitor 
induced gene expression at a higher level than controls and other doses. 
 
Flow cytometric analysis was carried out to investigate the platelet-leukocyte 
heteroconjugates in whole blood stimulated with LPS and LPS in combination with platelet 
activating factor (PAF). Whole blood samples were stimulated for 2 h. LPS-stimulated whole 
blood was found to increase platelet interactions with monocyte with approximately 50% (not 
significant). Addition of both LPS and PAF resulted in a 3-fold significant enhancement of 
the conjugate formation. The binding of platelets to granulocytes decreased when LPS was 
added but the aggregates were observed to slightly increase when stimulated with LPS and 
PAF in combination. 
 
In conclusion, these experiments have demonstrated that inhibition of the PGE2 synthesis 
enhanced LPS-induced TF activity in whole blood monocytes and expression of the chosen 
proinflammatory cytokines. In platelet-monocyte interactions, platelets bound easily to 
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The interactions between platelets and leukocytes in the circulation have a key role in 
physiological and pathophysiological processes. Inflammatory and thrombotic events control 
various cardiovascular syndromes. In patients with type I diabetes mellitus, acute myocardial 
infarction, stroke and sepsis accumulating levels of platelet-leukocyte conjugates are observed 
in the circulation (Furman et al., 2001; Nijm et al., 2005). Plasma from patients with 
hypercholesterolemia and smokers also contain high amount of platelet-leukocyte conjugates 
(Lehr et al., 1997; Nijm et al., 2005). Circulating larger platelet-leukocyte aggregates are 
often an indication of plaque instability and ongoing vascular thrombosis and inflammation 
(Freedman & Loscalzo, 2002). In addition, platelet-leukocyte aggregates interact with 
atherosclerotic lesions indicating that cell-cell interactions between platelets and leukocytes 
may modulate and sustain inflammatory events at the vascular wall (Huo et al., 2003). 
 
In ongoing inflammation, or when arterial wall is injured, cells located around this site will be 
activated. The activation lead to subsequent release of receptors and activator molecules, 
resulting in increased amounts of these molecules exposed on the cell surface. Following the 
exposure of, for example P-selectin on activated platelets, leukocytes expressing the P-
selectin ligand, P-selectin glycoprotein-1 (PSGL-1), will bind stronger to platelets and thus 
also to the arterial wall (as reviewed in Weyrich et al., 2006). These interactions send 
intracellular signals into the leukocytes, which in turn increases the expression of surface 
receptors such as CD11b/ CD18 (integrin αMβ2,Mac-1) and the monocytic tissue factor (TF, 
CD142). Furthermore, such cell-cell interactions take part in the initiation of the atherogenesis 
process at vascular injury spots (Nakagomi et al., 2000). Thrombosis, atherosclerosis and 
sepsis are partly controlled through an inflammation process which starts in the circulation. 
The interactions between platelets, leukocytes and extracellular matrix are critical in the 
inflammation process as these interactions are sites for intercellular communication, transfer 
of information and formation of molecules which provide development and progression of the 
diseases (Lindemann et al., 2001). The platelets then release various critical signal molecules, 
such as platelet activating factor (PAF) and P-selectin, which in turn stimulate biosynthesis of 
the leukocytes’ secondary activator molecules. These molecules (PAF and P-selectin) interact 
and activate leukocytes to produce molecules such as interleukin 8 (IL-8), monocyte 
chemotactic protein 1 (MCP-1) and macrophage inflammatory protein 1 (MIP-1α). These 
molecules result in a further accumulation of leukocytes at the inflammatory point.   
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Together all these signal substances manifest the inflammation (Eilertsen & Østerud, 2005; 
Eilertsen & Østerud, 2004). It has earlier been indicated that leukotriene B4 (LTB4), 
prostaglandin E2 (PGE2), PAF and thromboxane A2 (TxA2) are important contributor 
molecules in upregulation and activation of TF (Eilertsen & Østerud, 2002; Eilertsen et al., 
2003; Østerud, 1992; Østerud et al., 1992). However, these effects still remain to be fully 
investigated and some of the remaining questions will hopefully be answered through this 
work. 
 
This thesis will give a brief introduction to blood coagulation and inflammation, including 
some background about bacterial lipopolysaccharide (LPS) as well as proinflammatory 
molecules and mediators such as tissue factor, arachidonic acid metabolites, cytokines, and 
enzymes. The aims of the studies are presented. Materials and methods used are presented 
including some theoretical background to the main methods/ techniques used in this study. 
Finally, this thesis will present various cellular activation responses to different inhibitors to 
regulate the amount of prostaglandins and leukotrienes, with respect to activity- and 
expression level of TF, cytokines, enzymes and intercellular communication. 
 
1.1. Inflammation 
The immune system is the body’s major defence systems and is composed of many 
specialized cell types that collectively protect the body from bacterial, parasitic, fungal, viral 
infections, and from the growth of tumor cells. Inflammation is one of the first responses of 
the immune system to infection involving the recruitment of immune cells to the site of injury. 
An inflammatory reaction serves to establish a physical barrier against the spread of infection 
and to promote healing of any damaged tissue following the clearance of pathogens. Many 
cell types (granulocytes, monocytes and macrophages) and mediators (thromboxane, 
leukotrienes, PAF, interleukins and tumor necrosis factors) are involved in this process. Some 
mediators are pro-inflammatory (increasing inflammation), others are anti-inflammatory 
(decreasing inflammation). 
 
Leukocyte such as T- and B-lymphocytes, granulocytes, monocytes, macrophages, natural 
killer (NK) cells and among other cells, and protein rich fluid are recruited from the 
circulation to fight infection in response to pro-inflammatory chemical mediators. The protein 
fluid mobilized to the injured tissue contains various proteins and materials to make foreign 
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substances easier to phagocytize. Exudate is the collective term of leukocytes and the protein 
rich fluid. They account for the swelling at the sight of damaged tissue. At the local site of 
injury, the pro-inflammatory products are released. The released products enhance neutrophils, 
T- and B cells, platelets and coagulation factors to produce anti-inflammatory mediators to 
counteract the local inflammation. The inflammatory process lasts until the damaged tissue 
has been removed and repaired. 
 
1.2. Initiation of blood coagulation 
The process of blood clotting and then subsequent dissolution of the clot, following repair of 
the damaged tissue is termed hemostasis. Upon vessel damage, four major events occur in a 
set order following the loss of vascular integrity: 1. vascular constriction, which limits the 
flow of blood to the area of injury, 2. platelets become activated by collagen and aggregate at 
the site of injury, forming a temporary, loose platelet plug, 3. to ensure stability of the initially 
loose platelet plug, a fibrin mesh (also called clot) forms and entraps the plug, 4. finally, the 
clot is dissolved in order for normal blood flow to resume. This dissolution of clot occurs 
through the action of plasmin. 
 
When blood comes into contact with foreign matter like tissues or other surfaces, platelets and 
leukocytes agglutinate and blood becomes exposed to traces of TF. The exposed TF then 
initiates a reaction that leads to the conversion of prothrombin to thrombin in the presence of 
calcium ions, which converts fibrinogen into the fibrin strands of the blood clot. Destroyed 
tissue cells provide a second and major source of TF, which causes the blood to clot more 
rapidly at a wound site (Rapaport & Rao, 1995). 
 
The formation of fibrin during haemostasis stems from local exposure of TF and the 
consequential activation of the coagulation cascade leading to the generation of thrombin at 
the site of injury. TF serves as a cellular receptor and cofactor for plasma factor VIIa (FVIIa), 
the enzyme initiating the coagulation protease cascade, leading ultimately to the generation of 
thrombin and fibrin (Eilertsen & Østerud, 2005) . 
 
Coagulation is highly conserved throughout biology, and involves both a cellular (platelet) 
and a protein (coagulation factor) component. The system in humans has been the most 
extensively investigated and is therefore the best understood. 
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1.3. Introduction to tissue factor 
Tissue factor, the protein component of tissue thromboplastin (Bach, 2006), also known as 
thromboplastin, coagulation Factor III and CD142, is a 47 kDa transmembrane glycoprotein. 
TF is a high-affinity, cell-surface receptor and essential cofactor for the serine protease factor 
VIIa (Bach et al., 1986; Broze, 1982). The TF-VIIa complex activates factor X (FX) directly 
and indirectly via factor IXa (FIXa) generation, which lead to thrombin formation. The ability 
of TF to serve as a cofactor in the initiation of both the extrinsic and the intrinsic coagulation 
pathways underscores its critical role in coagulation (Rapaport & Rao, 1995).  
 
Expressed TF has a large extracellular domain (219 residues), a hydrophobic transmembrane 
domain (23 residues) and a cytoplasmic carboxyterminal domain (22 residues) (Morrissey et 
al., 1987; Spicer et al., 1987), Figure 1.  
TF
 
Figure 1. Tissue factor model. This TF model shows the extracellular part, which is located outside 
the cell and binds FVIIa, and transmembrane part, an intracellular domain, which is involved in the 
signaling function of TF. (Modified from Lwaleed et al., 2007). 
 
The structure of TF consists of three domains. Domain 1 of TF is located outside the cell and 
binds FVIIa. The binding of factor VIIa to TF occurs via protein-protein interactions by both 
molecules. Factor VIIa consists of several domains. One of these domains, the carboxylated 
GLA domain, binds in the presence of calcium to negatively charged phospholipids. Binding 
 4
Introduction 
of VIIa to negatively charged phospholipids greatly enhances the protein-protein binding of 
VIIa to TF. Domain 2 of TF crosses the hydrophobic membrane, and domain 3 is involved in 
the signaling function of TF. 
 
TF is primarily located in the adventitia of blood vessels (the outermost part of arteria, i.e. 
fibroblast), and it is believed to come into contact with blood only after vascular damage 
(Drake et al., 1989; Wilcox et al., 1989). TF is a constituent of both the subendothelial layer 
of the vascular wall and the extravascular tissue. It thereby forms a protective lining around 
the blood vessels and is ready to activate blood coagulation if vascular integrity is 
compromised (Ryan et al., 1992). Endothelial cells and blood monocytes (in contact with the 
bloodstream) do not constitutively express functional TF and do not have intracellular stores 
of TF (Lwaleed et al., 2007). Functional (active) TF is not normally expressed by cells within 
the bloodstream except in trace amounts in circulating monocytes (Østerud et al., 2007). 
However, gene transcription and subsequent protein expression can be induced in monocytes 
and macrophages by gram-negative bacterial lipopolysaccharide (endotoxin) or complement- 
and immune complexes (Amirkhosravi et al., 1996; Østerud et al., 1990; Roth, 1994). 
 
1.3.1. Forms of tissue factor 
There are three forms of TF which have been described, 1. free TF (includes a soluble, 
alternatively spliced TF in plasma resulting from alternative splicing of primary RNA 
transcripts (Bogdanov et al., 2003; Bogdanov et al., 2006)), 2. another soluble TF which is a 
truncated form of TF generated from a proteolytic cleavage at or near the linkage between the 
transmembrane and extracellular domains of the TF molecule, which forms protein fragments 
(Morrissey, 1991), and 3. membrane-bound TF, which includes cellular TF (found in vivo on 
fibroblasts, smooth muscle cells, monocytes, macrophages, and tumor cells) and lipid-vesicle-
bound TF (found in urine or semen). “Blood-borne” TF is in addition to the two soluble forms, 
a full length plasma TF which circulates in association with cell-derived membrane 
microparticles and TF-bearing microparticles. This type of TF arises mainly from monocyte-
macrophage membrane-lipid rafts or from regions of high raft content. 
 
Cellular membrane-bound TF is found in surface-, encrypted- and intracellular pool. On the 
plasma membrane, TF resides mostly in a cryptic configuration. The release of TF often 
referred to as de-encryption, coincides with an increase in cell-surface phosphatidylserine, 
which results in apoptosis and necrosis (Lwaleed et al., 2007). 
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It is believed that monocytes are the only circulating cells which synthesize and express TF 
upon stimulation. However, some studies have reported that neutrophils and platelets also 
may be able to synthesize and express TF (Giesen et al., 1999). Studies from Østerud and 
colleagues have indicated that granulocytes and platelets in whole blood do not express 
significant amount of TF antigen or activity but may acquire expressed TF upon stimulation 
with LPS or LPS in combination with phorbol myristate acetate (PMA) or tumor necrosis 
factor alpha (TNF-α) (Østerud, 2000; Sovershaev et al., 2007). The results from these studies 
suggest that the TF activity measured in granulocytes probably results from monocyte-derived 
TF-rich microparticles strongly bound to granulocytes (Østerud, 2000). 
 
1.3.2. Regulation of tissue factor expression and activity 
In addition to TF expression in adventitia of blood vessels, brain (astrocytes) (Eddleston et al., 
1993), lung (bronchiolar and alveolar cells), heart (cardiac monocytes) (Luther & Mackman, 
2001), kidney (tubular cells), and placenta (trophoblasts) (Lwaleed et al., 1999), TF is also 
found to be expressed in a number of embryonic cells including epithelial and smooth muscle 
cells (review, Siegbahn, 2000). 
 
The human TF gene is located on chromosome 1. The TF promoters are organized in a way 
which allows the gene to be inducible- (monocyte, macrophage and endothelial cells) and 
constitutive (fibroblast and epithelial cells) regulated (as reviewed in Tremoli et al., 1999). 
There are five putative transcription-factor sites, which are responsible for basal TF-gene 
expression, and two regulatory enhancers (proximal and distal) on the TF gene promoter 
(Moll et al., 1995).  
 
In vivo TF-FVII/FVIIa complex activity is regulated in an FXa-dependent manner by the TF-
pathway inhibitor (TFPI). Although TFPI reacts directly with the TF-FVIIa complex, the 
efficiency of this reaction is significantly increased after TFPI binds FXa, which provide a 
feedback-inhibition pathway that limits coagulation activation. Moreover, TFPI down 
regulates cell-surface TF in monocytic cells through the low-density lipoprotein-receptor-
related, protein-1 (LRP-1)-dependent pathway (Hamik et al., 1999). This down- regulation is 
thought to be achieved via a mechanism involving the ability of TFPI to bridge TF-FVIIa 
complex to LRP-1 so that the multiprotein complex is internalized as an intact unit (review, 





Lipopolysaccharide from gram-negative bacteria induces production and exposure of TF on 
the surface of circulating monocytes. It is a much used study model for investigating the 
molecular reaction and interactions connected to TF and inflammation. Once LPS comes in 
contact with host cells (i.e. monocytes, macrophages or neutrophils) a cluster of 
proinflammatory responses are generated (Lund, 2004). LPS-stimulated monocytes also 
release prostanoids such as thromboxanes A2 and prostaglandin E2 which have a feedback on 
platelets. 
 
The outer membrane of gram-negative bacteria is composed of a lipid and a polysaccharide 
(carbohydrate) joined by a covalent bond. The resulting macromolecule is known as 
lipopolysaccharide. LPS contribute greatly to the structural integrity of bacteria and protects 
the membrane from certain kinds of chemical attacks. LPS is also essential for bacterial 
growth and viability by participating in the physiological membrane function (Nikaido & 
Vaara, 1987).  
 
1.4.1. LPS structure 
Figure 2 shows a schematic representation of a gram-negative lipopolysaccharide. 
 
Figure 2. General structure of Gram-negative LPS. Capital letters represent sugar residues; Glc, D-
glucose; Gal, D-galactose; GlcN, D-glucosamine; GlcNAc, N-acetyl- D-glucosamine; Hep, L-glycero- D-
manno-heptose; KDO, 2-keto-3-deoxy- D -manno-ocotnate; AraN, 4-amino- L-arabinose; P, phosphate; 





Structurally, LPS can be divided into three separate regions, a lipid region, the lipid A, and a 
covalently bound hydrophilic heteropolysaccharide chain. The heteropolysaccharide chain is 
often branched and subdivided into the core and the O-specific chain (Luderitz et al., 1982). 
 
The O-chains are commonly highly hydrophilic and are made up by a sequence of identical 
oligosaccharides, the repeating units. It is the outermost part of the LPS molecule (Luderitz et 
al., 1982). The average length of O-chains varies from one species to another. An SDS-
polyacrylamide-gel electrophoresis investigation of the LPS of Salmonella Typhimurium  
revealed an average length of 7-10 repeating units, but a high degree of heterogeneity was 
seen in Palva & Mäkelä (1980). The O-polysaccharide part of the LPS is the major target by 
host antibodies and is thus referred to as the O-antigens (review, Erridge et al., 2002; Wiese et 
al., 1999). 
 
The core structures express less diversity than O-chains. This section is composed of 
unusually sugars such as Kdo and Hep, in addition to glucose, galactose and glucosamine. 
 
Lipid A is the highly hydrophobic lipid anchor, and is the toxic part of the LPS molecule, its 
structure is highly conserved among different bacterial groups. The structure is composed of a 
β- D-glycosamine (GlcN)-(1-6)-α- D-GlcN disaccharide backbone carrying two phosphoryl 
groups. Up to four acyl groups are attached by ester or amide linkage to this structure, which 
in turn can be substituted by more fatty acids to give LPS molecules with up to seven acyl 
chains (Luderitz et al., 1982). 
 
LPS strongly stimulates both the innate immune response and inflammation in humans and 
other mammals. It is a well known and frequently used inducer of TF expression on 
monocytes and of cytokine and eicosanoid production in in vitro models. 
 
1.4.2. Escherichia coli LPS 
The LPS of E. coli alone can be the causative agent of a number of diseases, including 
travelers’ diarrhea and infantile diarrhoea. The human gut contains many grams of E. coli 
LPS. The release of large amounts of LPS into the blood stream (e.g. can occur following 
surgery), can lead to multiple organ failure, shock and potentially death (Erridge et al., 2002). 
The high toxicity of E. coli LPS can be explained to a large extent by its structure (Figure 3). 
The hexa-acyl disphosphorylated lipid A with acyl chains C12-C14 is believed to provide 
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maximal activation of toll-like receptor 4 (TLR-4), and hence activation of monocytes. 
However, the optimum structure for cellular activation is not the same as the optimum 
structure for cell binding. Experiments revealed that the optimum structure for binding to cells 
is a bisphosphorylated disaccharide together with some fatty acids and in no particular 
arrangement. Structures that bind well to cells do not necessarily induce strong monokine 
release. Nevertheless, it is the number, nature and distribution of fatty acids, i.e. the acylation 
pattern of the lipid A which determines the endotoxic activity of these compounds (review, 




Figure 3. E. coli lipid A structure. Structure shown is in complete form (adapted from Erridge et al., 
2002). LPS used in the present study is from the E.coli 026:B6 strain. 
 
1.5. Arachidonic acid and its metabolites (eicosanoids) 
One of the most important classes of lipid mediators is known as eicosanoids. The word 
eicosa is Greek and means twenty; twenty carbon fatty acid derivatives. Eicosanoids are 
potent local hormones that are released by the cells to self-activate (autocrine) or activate 
nearboring cells (paracrine). These signaling are then rapidly inactivated.  
 
In humans, the biosynthesis of eicosanoid starts with arachidonic acid (AA) oxygenation. The 
products of eicosanoids include prostanoids (prostaglandins, prostacyclins and thromboxanes), 
leukotrienes, and various epoxy, hydroxyl and hydroperoxy fatty acids [epoxyeicosatetraenoic 
acids (ETEs), hydroxyeicosatetraenoic acids (HETEs) and hydroperoxyeicosatetraenoic acids 
(HPETEs)] (Maclouf et al., 1998; Samuelsson, 1979).  
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Arachidonic acid (5,8,11,14-eicosatetraenoic acid, C20:4, n-6), is a long chain 
polyunsaturated fatty acid and become released from the cell membrane by the action of 
phospholipase A2 on membrane phospholipids. Metabolites of arachidonic acid (eicosanoids) 
have been implicated as mediators or modulators of a number of physiological functions and 
pathologic conditions, Figure 4 (Samuelsson, 1983). It is reported that eicosanoids can be 
generated in human skin and exert proinflammatory and immunoregulatory actions through 
their effects on blood vessels and inflammatory cells (Ruzicka, 1990). A number of skin 
diseases such as ultraviolet dermatitis (Miller et al., 1994), atopic dermatitis (Ikai & Imamura, 
1993), and urticaria (Sabroe & Greaves, 1997) are predicted to form due to the action of 
eicosanoids, since eicosanoids affect both blood vessels and inflammatory cells.  
 
The rate limiting step for eicosanoid formation starts with esterification of the arachidonic 
acid at the sn-2 position of cell membrane phospholipids. Activated phospholipase A2 
catalyzes ester hydrolysis and the release of the free acid. Arachidonic acid can be 
subsequently transformed by several pathways, but these metabolic fates depend on the cell 
type and its specific complement of enzymes (Needleman et al., 1986). 
 
Figure 4. Eicosanoids mechanisms. Eicosanoids bind to individual receptor systems and transduce 




The arachidonic acid pathway constitutes one of the main mechanisms for the production of 
pain and inflammation, as well as controlling homeostatic function. The pathway produces 
different classes of end products (Figure 5): 
1. The prostaglandins (from cyclooxygenase metabolism) 
2. The prostacyclines PGI2 
3. Thromboxane TxA2 
4. The leukotrienes (from lipoxygenase metabolism) 
 
Figure 5. Biosynthesis of Eicosanoids from arachidonic acid. The metabolism of arachidonic acid 
is a highly branched pathway. Phospholipase A2, prostaglandin H synthase, and 5-lipoxygenase are 
three important enzymes regulating eicosanoid synthesis. (Modified from Medical Center, 2004). 
 
1.5.1. Biosynthesis of prostaglandins 
The first enzyme unique to the synthesis of prostaglandins, prostacyclins and thromboxanes 
(Figure 5) is prostaglandin H synthase, or better known as cyclooxygenase (COX). The COX 
pathway involves a series of peroxidation and cyclizations of arachidonic acid, leading 
initially to unstable intermediates and prostaglandin G2 and H2 (PGG2 and PGH2) (review, 
Ikai, 1999). There are two COX isoforms, COX-1 and COX-2, each having specific catalytic, 
regulatory and tissue distribution properties. The former enzyme is responsible for basal, 
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constitutive prostaglandin synthesis, whereas COX-2 is important in various inflammatory 
and can be induced by cytokines, growth factors and tumor promoter (DeWitt, 1991). 
 
The unstable intermediate, PGH2, undergoes isomerization or reduction, and are converted to 
other products by their respective enzymes (Figure 6) (Urade et al., 1995). Thromboxane 
synthase is found in platelets and macrophages, prostacyclin synthase in endothelial cells and 
PGF synthase in uterus, while two types of PGD synthase are found in brain and mast cells. 
Microsomal PGE synthase (mPGES), a member of the MAPEG 
(membrane-associated proteins in eicosanoid and glutathione metabolism) family, is 
responsible for the PGE2 synthesis (Jakobsson et al., 1999). 
 
Prostaglandins act as autocrine and paracrine lipid mediators (i.e. they signal at or 
immediately adjacent to their site of synthesis). They are not stored but are synthesized de 
novo from activated cells. These cells are activated by mechanical trauma or by specific 






















Figure 6. Prostaglandin synthesis and actions. Only a few of the many diverse activities of 
prostaglandins are shown here. Arachidonic acid release from membrane lipids and metabolism by 
COX-1 or COX-2 to the intermediate PGH2. Formed prostaglandin products may undergo facilitated 
transport from the cell through a known prostaglandin transporter (PGT) or other carrier to exert 
autocrine or paracrine receptors EP1, EP3, DP1, DP2, IP, and TPα on the cell type indicated. 
Prostaglandins could potentially enter the nucleus and activate nuclear hormone receptors such as 
PPAR-γ. PGES – PGE synthase; PGDS – PGD synthase; PGIS – prostacyclin synthase; TxS – 
thromboxane synthase. OVLT in POA – the organum vasculosa lamina terminalis at the midline of the 
preoptic area. X mark – site of inhibition by NSAIDs, celecoxib and rofecoxib. (Figure based on Funk, 
2001). 
 
1.5.1.1. Thromboxanes – biologically active compounds derived from prostaglandin 
endoperoxides 
Thromboxane (Tx) is a member of the eicosanoids family and a potent vasoconstrictor 
(Samuelsson et al., 1978), and causes both platelet aggregation (Hamberg et al., 1975) and 
white blood cell adhesion (Spagnuolo et al., 1980).There are two major thromboxanes, 
namely thromboxane A2 and thromboxane B2 (TxB2). TxA2 is a metabolitic oxidation product 
derived from arachidonic acid in cyclooxygenase and thromboxane synthase dependent 
reactions (Arita et al., 1989; Hamberg et al., 1975). 
 
Thromboxane is named for its role in clot formation (thrombosis). Hamberg et al. 
demonstrated in 1975 a substance which was former known as rabbit aorta contracting 
substance (RCS). This substance was a chemically unstable metabolite of prostaglandin 
endoperoxides and was predominantly produced in platelets, they named it thromboxane A2 
(Hamberg et al., 1975). TxA2 is rather unstable and is rapidly hydrolyzed into the almost 
inactive and stable thromboxane B2 with a very short half-time in physiological solutions (ca. 
30 sec) (Arita et al., 1989). TxA2 is a potent inducer of platelet aggregation and a constrictor 
of vascular and respiratory smooth muscles (Svensson et al., 1976; Svensson et al., 1977). It 
has been postulated to be a mediator contributing to the pathophysiology of a variety of 
disease processes, such as thrombosis, atheroscleoris and myocardial ischemia (Arita et al., 
1989). TxA2 is released in substantial amount by activated platelets, and has also been 
demonstrated to be the principal product of the COX pathway in monocytes (Caughey et al., 
1997). The production of TxA2 is dependent on COX. The COX-1 inhibitors such as aspirin 
will decrease the production and redirect AA metabolism to other products through the 
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lipoxygenase pathways. Caughey et al. found in 1997 that if thromboxane production is 
inhibited in stimulated monocytes, both TNF-α and IL-1β productions decrease (Caughey et 
al., 1997). However, the same group proposed later that TxA2, through the activation of the 
mitogen-activated protein kinase (MAPK) pathways helps upregulate regulate COX-2 
synthesis and prostacyclin synthesis as demonstrated in human umbilical vein endothelial 
cells (HUVEC) (Caughey et al., 2001). 
 
1.5.1.2. Cyclooxygenases 
Prostaglandin endoperoxide H synthases-1 and 2 (PGHS-1 and 2) catalyze the committed step 
in prostanoid synthesis (Smith & DeWitt, 1996; Smith et al., 1996). The generic names for 
these isozymes are cyclooxygenase-1 and 2 (COX-1 and COX-2). The COX enzymes are 
monotopically inserted in the endoplasmic reticulum (ER) and nuclear membrane with the 
substrate binding pocket precisely orientated to take up released arachidonic acid (Smith et al., 
2000). These two isozymes have very similar active site structures, catalytic mechanisms, 
products and kinetics. However, there are structural differences between them which are of 
important for pharmacological and biological consequences. First, the active site of COX-2 is 
larger and more accommodating than that of COX-1. Second, although the gross kinetic 
properties of the enzymes are nearly identical, COX-1, but not COX-2, exhibits negative 
allosterism at low arachidonate concentrations. This difference may permit COX-2 to 
compete more effectively for newly released arachidonate when the isozymes are expressed in 
the same cell (Smith et al., 2000). 
 
COX-1 is a constitutive enzyme whose expression is regulated developmentally. This enzyme 
produces prostaglandins in the ER, which exit cells and signal through cell surface G protein 
linked receptors (as reviewed in DeWitt & Smith, 1995). Prostaglandins produced by COX-1 
are thought to mediate physiological responses to circulating hormones that require constant 
or rapid modulation or both. COX-1 is expected to be expressed at higher concentrations in 
tissues and in cells where prostaglandins have specialized signaling functions, such as kidney, 
stomach, platelets and vascular endothelium (DeWitt & Smith, 1995). 
 
COX-2 is an inducible enzyme that is normally absent from cells, but is expressed in response 
to growth factors, tumor promoters or cytokines. In contrast with COX-1 which forms 
products on the ER, COX-2 produces prostaglandins within or on the nuclear envelope 
(Morita et al., 1995). One aspect of COX-2 function that is more clearly defined is its role in 
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inflammation. It is expressed at sites of inflammation and in monocytes and macrophages 
stimulated with lipopolysaccharide or interleukin-1 (IL-1). The expression of COX-2 is 
inhibited by anti-inflammatory glucocorticoids, both in vivo and in vitro, and by anti-
inflammatory cytokines such as IL-4 and IL-10 (DeWitt & Smith, 1995). 
 
These two enzymes are of particular interest because they are the major targets of 
nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin and ibuprofen and the 
COX-2 inhibitors Celebrex and Vioxx. They are also involved in a range of pathologies that 
for COX-1 includes thrombosis (Patrignani et al., 1994; Patrono, 1994), and for COX-2 
includes inflammation, pain, and fever (Riendeau et al., 1997; Zhang et al., 1997), various 
cancers, and Alzheimer’s disease (McGeer & McGeer, 1999). 
 
1.5.2. Biosynthesis of leukotrienes 
In contrast to its metabolism in the presence of PGHS, arachidonic acid may face different 
fates in other cell environments. Leukotrienes are made predominantly by inflammatory cells, 
such as polymorphonuclear leukocytes, macrophages and mast cells (Funk, 2001). 
The lipooxygenase pathway begins with the oxygenation of arachidonic acid to 5-, 12-, or 15-
hydroperoxyeicosatetraenoic acids. 5-lipoxygenase (5-LOX) is a soluble, non-heme-iron 
protein and, like PGHS, is expressed as distinct isoforms. The enzyme is located in the 
nucleus in some cell types and the cytosol of others, and catalyzes the first two steps of the 5-
lipoxygenase pathway (Ford-Hutchinson et al., 1994). The first step is the conversion of free 
arachidonic acid to 5-HPETE. Then 5-HPETE is converted to LTA4 with the concerted efforts 
of 5-lipoxygenase-activating protein (FLAP). This labile intermediate is the substrate for 
various enzymatic reactions that form a number of biologically important compounds. 
 
Depending on the cellular context, there are two subsequent metabolic routes from LTA4 that 
lead to the generation of bioactive eicosanoids (Figure 4 and Figure 5). The first one involves 
LTA4 hydrolase (LTA4H), which make a hydrolytic attack of LTA4 and yields LTB4, a potent 
neutrophil chemoattractant and stimulator of leukocyte adhesion to endothelial cells (Peters-
Golden & Brock, 2001; Samuelsson, 1983). The second route for LTA4 metabolism involves 
conjugation with glutathione by the enzyme LTC4 synthase to produce LTC4. LTC4 is further 
metabolized through the enzymatic cleavage of a glutamic acid to produce LTD4 (Figure 4). 
LTD4 in turn can be converted to LTE4. These three latter leukotrienes comprise the cysteinyl 
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leukotrienes, or an entity described as “slow-reacting substance of anaphylaxis” for its slow 
and sustained smooth muscle contracting abilities (Figure 5) (Samuelsson, 1983). 
 
The mechanism of leukotrienes actions are shown in Figure 7 below. The B-LT1 receptor that 
binds LTB4 with high-affinity elicits a toxin-sensitive Gi linked chemotatic response and 
stimulates neutrophil secretion. Interestingly, two subtypes of cysteinyl leukotrienes receptors, 
CysLT1 and CysLT2, mediate the actions of LTC4 and LTD4. CysLT1 is found on airway 
smooth muscle cells and vascular endothelial cells, while CysLT2 is detected in spleen, 



















Figure 7. Leukotrienes synthesis and actions. Upon cellular activation of a mast cell or macrophage, 
a cascade of cell activation events leading to leukotrienes biosynthesis occurs. The FLAP protein acts 
as a transfer protein and facilitates presentation to 5-LOX for conversion to LTA4. 5-LOX activity is 
inhibited by zileuton (Zyflo) (X mark). LTA4 is further metabolized into LTB4 by LTA4 hydrolase. An 
uncloned transporter facilitates the efflux of LTB4 out of the cell, where it can act on neutrophils to 
elicit chemotaxis or to evoke other functions. LTA4 can also be converted to LTC4, by LTC4 synthase. 
The multidrug resistance-associated protein (MRP1) facilitate transfer of LTC4 out of the cell, where it 
is metabolized by extracellular-localized γ-glutamyl transpeptidase (GGT) or γ-glutamyl leukotrienase 
(GGLT) to LTD4, LTD4 activate CysLT1 receptors to cause bronchoconstriction and edema. Drugs in 




1.5.3. Anti-inflammatory drugs affecting arachidonic acid metabolism 
The development of anti-inflammatory pharmacological agents has been rapid and 
competitive. Non-steroidal anti-inflammatory agents (e.g. aspirin), act by inhibiting the COX 
enzymes in cells of the tissues at the inflamed site. The result is a block in the conversion of 
arachidonic acid, which is liberated from membrane phospholipids, into prostaglandins, 
prostacyclin, and thromboxane. The link between aspirin and prostaglandins were established 
in 1971. Aspirin inhibits the cyclooxygenase activity of prostaglandin H synthase by 
acetylating the hydroxyl group of a unique serine residue, this inhibition is irreversible 
(Medical Center, 2004) thus new protein synthesis is required for the recovery of 
prostaglandin synthesis. 
 
Most NSAIDs (e.g. ibuprofen, celecoxib, flurbiprofen, indomethacin) act by different 
mechanisms. For instance, ibuprofen is a reversible inhibitor of PGHS activity, while 
indomethacin exhibits a complex, time-dependent inhibition. 
 
Steroidal anti-inflammatory drugs are natural and synthetic steroids with glucocorticosteroid 
agonist characteristics. Examples of these drugs are beclomethasone, budesonide and 
dexamethasone. Corticosteroids bind to cytosolic or nuclear receptors and regulate the 
transcription of target genes. It is likely that corticosteroids carry out the inhibition of 
phospholipase A2. This inhibition will prevent the mobilization of arachidonic acid and other 
pro-inflammatory eicosanoid precursor fatty acids. As a result, the synthesis of all eicosanoids 
will be blocked. 
 
Aspirin – COX- 1/2 inhibitor (Cayman Chemical Company) 
Aspirin, also known as acetylsalicylic acid (ASA), is widely used as an analgesic, antipyretic 
and anti-inflammatory agent. Aspirin is a potent inhibitor of prostaglandin synthesis (Vane, 
1971). The compound acetylates serine-529 and serine-516 in the active site of the COX-1 
and COX-2 enzymes, respectively. This deactivates the COX enzymes in an irreversible 
manner (Loll et al., 1995). Aspirin is 170-fold more potent in inhibiting COX-1 than COX-2 
(Vane et al., 1998), and low-dose aspirin is expected to inhibit cyclooxygenase-1 only 
(Macchi et al., 2006), whereas aspirin at higher doses is anti-inflammatory due to inhibition of 
COX-2. The antithrombotic effect of aspirin is primarily a result of and prevent thromboxane 
A2 platelet activation by interfering with the biosynthesis of thromboxanes A2 and inhibition 
of TxA2-dependent platelet aggregation (Macchi et al., 2006). The IC50 values for ovine 
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COX-1 and -2 are 0.75 mM and 1.25 mM, respectively, but concentrations of aspirin used in 
this study ranged from 2 μM as the lowest to 200 μM. 
 
CAY10404 – selective COX-2 inhibitor (Cayman Chemical Company) 
COX-2 was proved to be upregulated by bacterial lipopolysaccharide, cytokines, growth 
factors, and tumor promoters, which distinguished it from the primarily constitutively 
expressed COX-1 (Xie et al., 1991). COX-2 selective inhibitors provide a unique example of 
accelerated drug discovery and development.  
CAY10404 is one of the most selective inhibitors of COX-2, with a selectivity index (SI; SI = 
IC50 COX-1/IC50 COX-2) of > 500,000 (Cayman Chemical Company). 
The IC50 of COX-2 is < 1 nM. Concentrations used in this study were 50 nM as the lowest to 
5 μM. 
 
CAY10416 – dual COX-2/ 5-LOX inhibitor (Cayman Chemical Company) 
CAY10416 is a dual COX-2/ 5-LOX inhibitor. It is a potential therapeutic agent for 
inflammatory diseases and prostate cancer with IC50 values of 50 and 3 nM, respectively 
(Barbey et al., 2002). 
 
SC-560 – selective COX-1 inhibitor (Cayman Chemical Company) 
SC-560 is a member of the diaryl heterocycle class of cyclooxygenase inhibitors which 
includes celecoxib (Celebrex) and rofecoxib (Vioxx), which are selective COX-2 inhibitors. 
Unlike these inhibitors, SC-560 is a selective inhibitor of COX-1. Using the human 
recombinant enzymes, the IC50 value for the compound with respect to COX-1 is 9 nM. 
However, concentrations used in this study were from 50 nM to 5 μM. 
 
CAY10526 – mPGES-1/ COX-2 inhibitor (Cayman Chemical Company) 
Prostaglandin E2 is synthesized at sites of inflammation and plays an important role in 
different inflammatory diseases. It acts as a mediator of pain and inflammation and promotes 
bone destruction. The increased synthesis of PGE2 during inflammation can be accounted for 
by increased expression of both COX-2 and mPGES-1 (Claveau et al., 2003). 
CAY10526 is an inhibitor of PGE2 production through the selective modulation of mPGES-1 
expression. It dose-dependently inhibits PGE2 production in LPS-stimulated RAW 264.7 cells 
with an IC50 value of 1.8 μM without any effect on COX-2 expression (Guerrero et al., 2007). 
Doses used in the study were from 100 nM to 10 μM as the highest concentration. 
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MF63 – selective mPGES-1 inhibitor (Merck) 
Phenanthrene imidazole 3 (MF63) has been identified as a new potent, selective, and orally 
active mPGES-1 inhibitor. The compound is the first reported mPGES-1 inhibitor to 
demonstrate potency in a human whole blood (HWB) assay. When freshly collected blood 
was stimulated with LPS, the compound selectively inhibited the production of PGE2 with an 
IC50 of 1.3 μM with no concomitant TxB2 inhibition. This HWB IC50 is comparable to the 
ones of marketed coxibs (Riendeau et al., 2001). Doses used in the study were from 200 nM 
to 20 μM as the highest concentration. 
 
1.6. Cytokines 
Infection, cancer, and inflammation triggers production of immunological mediators termed 
cytokines. Cytokines are a group of proteins and peptides used as signaling compounds by 
organisms. These chemical signals are similar to hormones and neurotransmitters, which 
allow one cell to communicate with another. Cytokines have autocrine or paracrine effects 
that have the ability to affect several target cells through membrane receptors inducing gene 
activation and protein synthesis. Cytokines often promote (inflammatory) or inhibit (anti-
inflammatory) the synthesis of other cytokines, which in turn forms complex cytokine 
networks. Monocytes/ macrophages are one of the major sources of cytokine production in 
the body. The over 50 cytokines reported  are clustered into several classes, such as 
interleukins (IL), tumor necrosis factors, interferons (IFN) and chemokines (Boulay et al., 
2003; Langer et al., 2004). Among the proinflammatory cytokines, tumor necrosis factor α, 




After LPS infusion, TNF-α is the first cytokine to be detected in the circulation. TNF-α is an 
extremely potent peptide cytokine which serves as an endogenous mediator of inflammatory, 
immune and host defence functions. It is a product of monocytes during monocyte activation. 
TNF-α is also reported to be produced by other cell types, such as granulocytes, eosinophils, 
mast cells, T-lymphocytes, NK-cells and tumor cells, in response to certain stimuli (Jirro et al., 
1995). The term “tumor necrosis factor” refers to its ability to suppress certain tumor cells in 
the defense system of man (Waage et al., 1987).  Among other effects, this pivotal mediator 
of inflammation also activates leukocytes, enhances adherence of neutrophils and monocytes 
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to endothelium, and triggers local production of other proinflammatory cytokines (Tracey & 
Cerami, 1994). Moreover, the role of TNF-α in septic shock, cancer, rheumatoid arthritis, 
malaria, and other afflictions have been extensively investigated (Tracey & Cerami, 1994). 
 
1.6.2. Monocyte chemotactic protein- 1 
MCP-1 is a CC chemokine essential for monocyte recruitment in in vivo models of 
inflammation. MCP-1 induces the recruitment of other leukocytes such as T lymphocytes, 
eosinophils and basophils. It is mainly expressed by macrophages in response to cytokines 
such as IL-6, TNF-α and IL-1β. Upon stimulation, it can also be produced by a variety of cells 
and tissues, such as fibroblasts, endothelial cells or certain tumor cells. Adhesion of human 
monocytes to P-selectin, the most rapidly expressed endothelial tethering factor, increased the 
secretion of MCP-1 and TNF-α from leukocytes stimulated with PAF (Weyrich et al., 1995). 
Due to its target cell specificity, MCP-1 was postulated to play a pathogenic role in a variety 
of diseases characterized by mononuclear cell infiltration, including atherosclerosis, 
rheumatoid arthritis and allergic responses (Carr et al., 1994). Elevated levels of MCP-1 have 
also been found in connection with osseous inflammation (Graves et al., 1999) and 




Following an LPS stimulation, IL-1 release is typically observed to occur shortly after TNF-α 
liberation (DeForge et al., 1992). Interleukin-1 is one of the first described cytokines, and is 
seen to be expressed by white blood cells (leukocytes) as a mean of communication. In mid 
1980s scientist confirmed that IL-1 was actually composed of two distinct proteins, now 
called IL-1α and IL-1β, both pro-inflammatory cytokines are involved in immune defence 
against infection. These two molecules are produced by monocytes, macrophages, fibroblasts, 
keratinocytes, endothelial cells and other cell types. They are potent modulators of the acute 
phase, inflammatory, and immune responses (Dinarello & Savage, 1989). 
 
IL-1β biosynthesis is complex and regulated at multiple levels. The blood monocyte is found 
to be the best characterized cell to produce high levels of IL-1. However, there is controversy 
regarding the release of IL-1 by macrophages.  Suttles and colleagues (1990) and Beuscher et 
al. (1990) observed release of both IL–1α and IL–1β from LPS-stimulated macrophages. On 
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the contrary, other groups have reported that fresh human monocytes release IL-1β, but 
cultured monocytes and macrophages do not (Burchett et al., 1988; Wewers & Herzyk, 1989). 
Furthermore, the role of IL-1β in pathogenesis of estrogen-dependent cancers is found to be 
implicated in protumorigenic insults, cell proliferation, angiogenesis and cell adhesion. The 
IL-1βs stimulatory or inhibitory paracrine and/ or autocrine signals regulating the growth of 
estrogen-dependent tumors are concentration dependent. 
 
1.6.4. IL-8 
Interleukin 8 or neutrophil activating protein is a cytokine that functions as a neutrophil 
chemoattractant/ activator and as a lymphocyte chemoattractant. It is produced in response to 
LPS-stimulated monocytes, and in a variety of cell types (i.e. endothelial cells, fibroblasts, 
keratinocytes, lymphocytes), in response to inflammatory stimuli such as TNF-α and IL-1β 
(Yoshimura et al., 1987). IL-8 induces shape change, chemotaxis, release of granule contents, 
up-regulation of adhesion proteins, formation of bioactive lipids, and respiratory burst. IL-8 is 
expressed at high levels particularly in keratinocytes in skin diseases such as psoriasis and 
palmoplantar pustulosis (Gillitzer et al., 1991). It is also present in the synovial fluid of 
patients with inflammatory joint diseases. 
 
This chemokine has gained considerable attention because of its ability to attract and activate 
leukocytes and its undisputed role as mediators of inflammation. 
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2. AIMS of STUDY 
The aim of this thesis was to study the roles of prostaglandins by regulating their amount 
using different specific inhibitors. How these lipid mediators directly and indirectly influence 
the TF activity- and expression level (mRNA) of TF and proinflammatory cytokines involved 
in the intercellular communication important for inflammation, thrombosis, atherosclerosis 
and sepsis was investigated in whole blood. 
 
Furthermore, interactions between leukocyte subpopulations (of which monocytes and 
granulocytes) and platelets were examined using flow cytometric analysis. Whole blood 
stimulated with LPS and LPS and PAF in combination was analyzed for the amount of 
adherent platelets in the granulocyte and monocyte windows. 
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3. MATERIALS and METHODS 
3.1. REAGENTS 
Table 1. Reagents and solutions. 
Compound Supplier Catalogue no/ note 
Sterile saline Invitrogen, USA  
Sterile distilled water Millipore Ultra Pure Distilled water 
LPS  Difco Laboratories, Detroit, 
USA 
Lipopolysaccharide B E.coli 
026:B6 
Lymphoprep Axis-shield POC AS, Oslo, 
Norway 
Lot 01C2482552 
Fragmin Pfizer  
DMSO Sigma chemical co, USA  
PAF Sigma- Aldrich, inc. USA  
Tempus solution Applied Biosystems, USA  
95% or better alcohol Arcus kjemi AS, Norway  
FACS™ Lysing Solution BD Biosciences, San Jose, Ca, 
USA 
 
Anti-CD14 – APC BD Biosciences, San Jose, 
Ca, USA 
Anti-CD16 – PE BD Biosciences PharMingen 
Anti-CD62P (P-sel) – FITC BD Biosciences PharMingen 
Anti-CD42a - FITC Serotec, UK 
 
Fluorescent dyes conjugated 
with antibodies 
 
Table 2. Kits used in this thesis. 
Kit Supplier Used for 
5 Prime PerfectPure RNA Blood kit 5 Prime GmbH, Germany 
Vacuette Tempus Blood RNA Tube Applied Biosystems, USA 
RNA isolation 
 
High-Capacity cDNA Reverse Transcription Kits Applied Biosystems, USA cDNA synthesis 








Materials and Methods 
Table 3. Instruments used in this study. 
Instruments Supplier 
Spectrophotometer, Thermo max microplate 
reader  
Molecular Devices 
7900 HT Fast Real-Time PCR systems Applied Biosystems, Singapore 
Nanodrop, NanoDrop® ND-1000 Saveen Werner (NanoDrop Technologies, USA) 
Centrifuges, Megafuge 1.0 Heraeus Sepatech 
Table centrifuge, MiniSpin eppendorf VWR™ International 
Cold centrifuge, Minifuge RF Heraeus Sepatech 
Horizontal shaker, G24 Environmental incubator 
shaker 
New Brunswick Scientific Co. Inc, Edison, N.J, 
USA 
Heating device (for cDNA synthesis) Grant, Dan Meszansky AS 
FACSAriaTM Cell Sorter BD Biosciences, USA 
APT. line® CB CO2 Incubators BINDER GmbH, Tuttlingen, Germany 
 
3.1.1. Preparation of reagents  
LPS, with a stock concentration of 50 μg/ mL, was diluted 1:100 with sterile saline before 
addition to the samples. This gave a final concentration of 5 ng/ mL.  
 
PAF stock (in DMSO) concentration was 10 mM. 4 μL of the working (5 mM) dilution 
(diluted in sterile saline) was added to 2 mL blood. This gave final concentration 10 μM.  
 
FACS lysis solution mix was prepared by 1:10 dilution of the 10X FACS lysing solution 
concentrate. 
 
Phosphate buffer saline (PBS), pH 7.2, was made by diluting 10X stock PBS solution with 
destilled H2O. 10X PBS was composed of 207.72 g Na2HPO4 x 12H2O, 26.52 g NaH2PO4 x 
2H2O, and 39.739 g sodium chloride. 
 
Aspirin: COX-1 (COX-2) inhibitor (Cayman Chemical), Mw 180.2 
Aspirin was supplied as a crystalline solid. Aspirin is soluble in organic solvents such as 
ethanol, DMSO, and dimethyl formaide (DMF). Preparation of 200 mM aspirin stock solution 
(41 mg/mL): 20 mg aspirin was solved in 555 μL DMSO. The aspirin-stock was frozen in 10 
μL aliquots. To make the working solution, 10 
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μL aliquot was further diluted 1:10 with ice-cold saline, which gave a working concentration 
of 20 mM. Other concentrations were made from this solution. 
 
SC-560: selective COX-1 inhibitor (Cayman Chemical), Mw 352.7 
SC-560 was supplied as a crystalline solid, and the compound is soluble in organic solvents 
such as ethanol, DMSO, and DMF. Ten microliter 5 mM aliquots of SC-560 were prepared by 
solving 1 mg of the chemical with 567 μL DMSO. The working solution with a concentration 
of 500 μM was made by adding 90 μL ice-cold saline to the 10 μL freeze-stock. 
 
CAY10404: selective COX-2 inhibitor (Cayman Chemical), Mw 367.4 
CAY10404 was supplied as a crystalline solid and it is soluble in organic solvents such as 
ethanol, DMSO, and DMF. 1 mg of CAY10404 was solved in 544 μL DMSO, and the 
solution was frozen in 10 μL 5 mM aliquots. To make the working solution, 10 μL aliquot 
was diluted 1:10 with ice-cold saline, which gave a working solution of 500 μM. Further 
dilutions were made from this working solution. 
 
CAY10416: dual COX-2/ 5-LOX inhibitor (Cayman Chemical), Mw 536.6 
CAY10416 was supplied as a crystalline solid. It is soluble in organic solvents such as ethanol, 
DMSO, and DMF and a 5 mM solution of the compound was prepared by solving 1 mg of 
CAY10416 was solved into 372 μL DMSO and frozen in 10 μL 5 mM aliquots at -20°C. A 
500 μM working solution was made by adding 90 μL ice-cold saline to 10 μL aliquot freeze-
stock. 
 
CAY10526: mPGES-1/COX-2 inhibitor (Cayman Chemical), Mw 311.1 
CAY10526 was supplied as a crystalline solid. The compound is soluble in organic solvents 
such as ethanol, DMSO and DMF. One miligram CAY10526 was solved in 321 μL DMSO 
and froze down in 10 μL 10 mM aliquots at -20°C. The working solution of 1 mM was made 
by adding 90 μL ice-cold saline to the 10 μL freeze-stock. 
 
MF63: selective and orally active mPGES-1 inhibitor (Merck), Mw 415. 
MF63 was kindly provided by Merck. Ten microliter 20 mM aliquots were frozen down at -




Materials and Methods 
3.2. METHODS 
3.2.1. Blood sampling 
Venous blood was drawn from an anticubital vein in the forearm of healthy volunteers using a 
plastic syringe (BD Plastipak™, Spain) and a 19 gauge x 1.5” needle (BD Microlance 3™, 
Ireland). For all analyses blood was obtained between 9:00 and 10:00 a.m. immediately 
transferred into polycarbonate tubes (Nalge Nunc International, NY, USA) containing 
fragmin to a final concentration of 10 μL/ mL blood, and mixed by gentle inversion. The 
samples were kept at room temperature for immediate use as indicated. All blood donors have 
been healthy volunteers recruited at the university campus. 
 
3.2.2. Whole blood assay 
Anticoagulated (fragmin, 10 μL/ mL blood) blood was aliquoted into sterile cell culture (6- or 
12 wells) plates. For 6-wells plates 2 mL blood aliquots were used and for 12-wells plates 1 
mL aliquots were used. After addition of the respective stimuli all samples were incubated at 
37°C in a 5% CO2 atmosphere at constant rotation as indicated under each experiment part. 
All assays were performed in duplicates. 
 
3.2.2.1. LPS time response: stimulation of whole blood – effects on mRNA expression of 
selected proinflammatory genes  
First, an LPS time response study was performed in order to determine the optimal incubation 
time for each proinflammatory gene/ assay to be investigated in the present study. As shown 
in table 4, whole blood was incubated with LPS (5 ng/ mL) or saline (as control) for the 
indicated incubation times (0 h, 0.5 h, 1 h, 1.5 h, 2 h, 4 h, 8 h, 12 h and 24 h). LPS was diluted 
in sterile saline to a final concentration of 5 ng/ mL from stock preparations. All samples were 
mixed gently and incubated at 37°C. The reactions were stopped by transferring the blood 
samples into polycarbonate tubes containing 2 mL Tempus solution. The blood-Tempus 
mixtures were vigorously shaken (10-15 s) and stored at -20°C until RNA isolation, see 
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Table 4. Incubation setup for LPS time response experiments. 
Volume blood in mL Volume reagent added in μL Incubation time (hour) 
990  + 10 LPS (5 ng/mL)  
990  + 10 saline 
0 
990 + 10 LPS (5 ng/mL) 
990 + 10 saline 
0.5 
990 + 10 LPS (5 ng/mL) 
990 + 10 saline 
1 
990 + 10 LPS (5 ng/mL) 
990 + 10 saline 
1.5 
990 + 10 LPS (5 ng/mL) 
990 + 10 saline 
2 
990 + 10 LPS (5 ng/ml) 
990 + 10 saline 
4 
990 + 10 LPS (5 ng/mL) 
990 + 10 saline 
8 
990 + 10 LPS (5 ng/mL) 
990 + 10 saline 
12 
990 + 10 LPS (5 ng/mL) 
990 + 10 saline 
24 
 
3.2.2.2. LPS time response: stimulation of whole blood – effects on TF activity  
Samples were prepared as in section 3.2.2.1, however, the reactions were stopped by adding 
100 μL of 2% EDTA. Subsequently, 1 mL ice cold saline was added to each sample, and the 
isolation of mononuclear cells was carried out, as described in section 3.2.3. Samples were 
subsequently subjected to tissue factor activity measurement, see section 3.2.4. 
 
3.2.2.3. Eicosanoid inhibition studies – effects on TF activity and mRNA expression of 
selected proinflammaotry genes 
In this part of the experiment, inhibitors of the arachidonic acid metabolism were used to 
explore the effects inhibition of eicosanoids in general and specifically of prostaglandins, on 
TF activity and proinflammatory gene expression. Whole blood samples were preincubated 
with the respective inhibitors (see tables 5, 6, 7, 8, 9 and 10) for 15 min. at 37°C, and 
subsequently incubated with LPS (5 ng/ mL) for another ninety minutes. After incubations the 
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Table 5. Setup for aspirin (COX-1/2 inhibitor) and subsequent LPS-stimulation of whole blood 
samples. 
15 min preincubation + 90 min incubation 
2 wells1 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL saline 
2 wells 980 μL blood + 10 μL aspirin (200 μM final) + 10 μL saline 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL aspirin (200 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL aspirin (20 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL aspirin  (2 μM final) + 10 μL LPS (final: 5 ng/ mL) 
 
Table 6. CAY10404 (selective COX-2 inhibitor) and subsequent LPS-stimulation of whole blood 
samples. 
15 min preincubation  + 90 min incubation 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL saline 
2 wells 980 μL blood + 10 μL CAY10404 (5 μM final) + 10 μL saline 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10404 (5 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10404 (500 nM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10404 (50 nM final) + 10 μL LPS (final: 5 ng/ mL) 
 
Table 7. CAY10416 (dual COX-2/5-LOX inhibitor) and subsequent LPS-stimulation of whole 
blood samples. 
15 min preincubation + 90 min incubation 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL saline 
2 wells 980 μL blood + 10 μL CAY10416 (5 μM final) + 10 μL saline 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10416 (5 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10416 (500 nM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10416 (50 nM final) + 10 μL LPS (final: 5 ng/ mL) 
 
Table 8. SC-560 (selective COX-1 inhibitor) and subsequent LPS-stimulation of whole blood 
samples. 
15 min preincubation  + 90 min incubation 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL saline 
2 wells 980 μL blood + 10 μL SC-560 (5 μM final) + 10 μL saline 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL SC-560 (5 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL SC-560 (500 nM final) + 10 μL LPS (final: 5 ng/ mL) 






                                                 
1 Per assay 
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Table 9. CAY10526 (mPGES-1/COX-2 inhibitor) and subsequent LPS-stimulation of whole 
blood samples. 
15 min preincubation  + 90 min incubation 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL saline 
2 wells 980 μL blood + 10 μL CAY10526 (10 μM final) + 10 μL saline 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10526 (10 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10526 (1 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL CAY10526 (100 nM final) + 10 μL LPS (final: 5 ng/ mL) 
 
Table 10. MF63 (selective mPGES-1 inhibitor) and subsequent LPS-stimulation of whole blood 
samples. 
15 min preincubation  + 90 min incubation 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL saline 
2 wells 980 μL blood + 10 μL MF63 (20 μM final) + 10 μL saline 
2 wells 980 μL blood + 10 μL DMSO:saline (1:10) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL MF63 (20 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL MF63 (2 μM final) + 10 μL LPS (final: 5 ng/ mL) 
2 wells 980 μL blood + 10 μL MF63 (0.2 μM final) + 10 μL LPS (final: 5 ng/ mL) 
 
3.2.3. Isolation of mononuclear cells for TF activity measurements 
1 mL of the incubated blood samples (after addition of EDTA) was mixed with 1 mL saline 
(1:1 ratio). This mixture of blood-saline was carefully applied on top of 1.7 mL lymphoprep 
in a new TT tube. The tube was centrifuged at 415 x g for 15 minutes, and the mononuclear 
band was collected and transferred to a new tube containing 4 mL 0.15 M NaCl and washed 
by centrifugation at 1450 x g for 10 min, this washing step was repeated twice with equal 
volume of saline each time. The supernatant was pipetted off and the pellet of mononuclear 
cells from 1 mL blood was resuspended in 200 μL sterile saline and frozen at -20°C until 
testing for tissue factor activity. 
 
3.2.4. Quantification of tissue factor activity  
Tissue factor activity was measured from isolated mononuclear cells based on the ability of 
TF to accelerate FX activation mediated by FVIIa, using bovine FV and barium citrate (BaCi) 
eluate (containing FVII, FX, and FII). A tissue factor standard curve was created through a 
serial dilution using ½ TBS-BSA buffer (0.025 mol/L Tris-HCl, 0.075 mol/L NaCl, 1 mg/mL 
BSA, pH 7.5). Resting samples (without LPS stimulation) were diluted 1:20 with the ½ TBS-
BSA buffer and samples with incubated with LPS were diluted 1:100 with the same buffer. 
Substrate Th-1 dissolved in sterile distilled water (2.5 mmol/L) was mixed in a 1:1 ratio with 
0.1 mol/L Tris-HCl, pH 9.5. 60 μL of preincubated mixture, composed of 5 μL cephalin, 100 
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μL bovine factor V, 50 μL BaCi eluate, in 4 mL ½ TBS-BSA buffer, was mixed with 15 μL of 
mononuclear cell sample or the TF standards. Following the addition of 15 μL of 50 mM 
CaCl2, the mixture was incubated for four minutes at 37°C. The thrombin generated was then 
quantified by adding 30 μL of Th-1 substrate and the mixture was incubated for an additional 
four minutes. The reaction was then stopped with 120 μL of 50% acetic acid. The TF activity 
is directly proportional to the amount of the coloured  product para-nitroanilide 
dihydroacetate (pNa) produced, which can be measured spectrophotometrically at  405 nm. 
 
3.2.5. RNA ISOLATION (PerfectPure RNA Blood Kit, 5 Prime GmbH, Germany) 
The frozen blood-Tempus mixtures were put at room temperature for approximately twenty 
minutes prior to RNA isolation. 
 
Sample homogenization 
For isolation, the blood-Tempus samples were transferred to 50 mL conical tubes containing 
1.5 mL of 95% ethanol (or higher), high-speed vortexed for 2 minutes, followed by 
centrifugation at 5800 x g for 60 min. at 4°C. The supernatant was poured off and the tubes 
blotted on clean absorbent papers for 2 min. 300 μL Lysis Solution was added to each tube 
and vortexed for 1 min. on high speed to dissolve the RNA pellet.  
 
RNA binding and wash 1 
The entire lysate was pipetted onto a purification column and centrifuged at 13400 rpm for 1 
min. The purification column was then transferred to a new collection tube, 400 μL of Wash 1 
Solution was added and centrifuged for 2 min. at 13400 rpm. 
 
DNase treatment 
The purification column was transferred to a new collection tube, 50 μL of DNase Solution 
was added to the entire column and it was incubated at room temperature for 15 min. 200 μL 
of DNase Wash Solution was added to the column, and centrifuged at 13400 rpm for 1 min. 
before addition of another 200 μL of DNase Wash Solution, and the column was centrifuged 
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Wash 2 
The purification column was transferred to a new collection tube. To the column, 200 μL of 
Wash 2 Solution was added, and it was centrifuged for 1 min. at 13400 rpm. This step was 
repeated with 2 min. centrifugation.  
 
RNA elution 
Finally, the purification column was carefully transferred to a new tube. 50 μL of Elution 
Solution was added and the tube was incubated at room temperature for 3 min. 1 minute 
centrifugation at 13400 rpm was carried out after the incubation. The purification column was 
discarded, and the collection tube containing the purified RNA was immediately put on ice. 
RNA was stored at -70°C. 
 
3.2.6. RNA concentration measurements 
RNA concentrations were determined using a NanoDrop® ND-1000 UV-Vis 
spectrophotometer (NanoDrop Technologies, North Carolina, USA). 
 
3.2.7. cDNA synthesis 
The High-Capacity cDNA Reverse Transcription Kit (ABI) was used for cDNA synthesis. 
The kit uses the random primer scheme for initiating cDNA synthesis. Random primers 
ensure that the first strand synthesis occurs efficiently with all species of RNA molecules 
present, including mRNA and rRNA. Reverse transcription of RNA was carried out in a 20 
μL final volume using 500 ng total RNA. The measured RNA concentration values were 
calculated and 2X RT Master mixture was prepared as shown in table 11 below.  
Table 11. Making the 2X Reverse Transcription (RT) Master Mix for cDNA synthesis. 
Reagents  + RT - RT 
 á μL x15 samples x5 μL samples 
10X RT buffer 2 30 10 
25X dNTP mix (100 mM) 0.8 12 4 
10X RT random primers 2 30 10 
MultiSribe™ RT 1 15 5 dH2O 
RNase free dH2O 4.2 63 21 
 10 μL 150 μL 50 μL 
 
Referring to the table, the volume of components needed to prepare one sample is indicated to 
the left, while the required number of reactions, for instance 15 totally, were calculated. This 
calculation also included additional reactions to provide excess volume for the loss that 
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occurred during reagent transfers. Samples without Reverse Transcriptase (-RT) were also 
prepared, and functioned as no amplification control during real-time PCR performance. 
10 μL of 2X RT mastermix was added into each tube containing 10 μL of RNA sample. The 
content was mixed by pipetting up and down before the tubes were centrifuged shortly (1-2 s) 
to spin down the contents and to eliminate any air bubbles. The tubes were placed on ice until 
loading on the thermal cycler as shown in table 12. 
 
Table 12. Thermal cycler condition. 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25 °C 37 °C 85 °C 4 °C 
Time 10 min 120 min 5 sec ∞ 
Event Binding of 
random primers to 
RNA 




After the thermal cycling 60 μL dH2O was added to each tube (1:4 dilution). The tubes were 
stored at -20 °C, if not immediately used for real time PCR. 
 
3.2.8. REAL TIME PCR 
Polymerase chain reaction generates copies of DNA/ cDNA template and is the most sensitive 
technique for detection of often-rare mRNA targets (cDNA) (Bustin & Nolan, 2004). Real-
time PCR is the continuous collection of fluorescent signal from one or more polymerase 
chain reactions over a range of cycles. It is the only truly quantitative method available. It 
offers rapid turn-around as no post PCR processing is necessary and since closed systems are 
used, the risk of contamination is reduced/ abolished. In quantitative real-time PCR 
fluorescent signals from each reaction is transformed into a numerical value representing each 
sample. In this study, real-time PCR analysis was performed with a 7900 HT Fast Real-Time 
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3.2.8.1. Real time PCR efficiency/ “standard curve” 
The assay efficiency is calculated from the slope of the plot of Ct versus log dilution series 
(“number of amplicon”) by the formula: 
 
                                               Efficiency = [10(-1/slope)] – 1                               
 
Efficiency is primarily an indication of how well the PCR reaction has proceeded. An assay 
can have an apparently acceptable efficiency of 95-100%. A 100% efficiency would have a 
slope of -3.32, which equals to a detection between 33.3-36.5 cycles, a y-intercept between 33 
and 37 cycles and an r2 of 1.00 (Adams, 2006). 
 
Procedure 
To make a standard curve, 5 μL of each sample with +RT was used to make a cDNA pool. From this 
cDNA pool, 15 μL was taken out and diluted as shown in table 13 below. 
 
Table 13. Standard curve dilution for real time PCR 
 Dilution 
1 1:2 15 μl of pooled samples + 15 μl dH2O 
2 1:5 10 μl (of 1) + 40 μl dH2O 
3 1:5 10 μl (of 2) + 40 μl dH2O 
4 1:5 10 μl (of 3) + 40 μl dH2O 
5 1:5 10 μl (of 4) + 40 μl dH2O 
 
Standards were run in triplicate. 
 
 
3.2.8.2. Primers and probes 
There are currently several techniques to perform quantitative real time PCR. However, in this 
thesis, the hydrolysis probes or Taqman method has been applied. The probe is an 
oligonucleotide with both a reporter fluorescent dye and a quencher dye attached. The 
Taqman assay utilizes the 5’-nuclease activity of the DNA polymerase to hydrolyze a 
hybridization probe bound to its target amplicon. The method is more sensitive and therefore 
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Procedure 
The primers (forward primer: FP, reverse primer: RP) and probes of the genes used in this study are 
shown in table 14. Cyclophilin A was run as a reference gene, while TF, TNF-α, IL-1β, IL-8, and 
MCP-1 as target gene. Probe modifications are also indicated as shown in the sequence. 
 




 Sequence written 5’ to 3’ Final 
concentratio
n (nM) 
Cyclophilin A  FP GTACTATTAGCCATGGTCAACCCC 200 
(reference 
gene) 
RP CAGTCAAAGGAGACGCGGCC 200 
 Probe 6-FAM-CGTCGACGGCGAGCCCTTG-BHQ-1 200 
TF FP CCCCAGAGTTCACACCTTACCT 200 




TNF-α FP CCCAGGGACCTCTCTCTAATC 400 
 RP  ATGGGCTACAGGCTTGTCACT 400 
 Probe 6-FAM-TGGCCCCAGGCAGTCAGATCATC-EDQ 200 
MCP-1 FP AGTCTCTGCCGCCCTTCT 400 
 RP GTGACTGGGGCATTGATTG 400 
 Probe GCCTGCTG (Roche Applied Science Universal Probe 
#40) 
100 
IL-1β FP CTGTCCTGCGTGTTGAAAGA 400 
 RP TTGGGTAATTTTTGGGATCTACA 400 
 probe AGCTGGAG (Roche Applied Science Universal Probe 
#78) 
100 
IL-8 FP GTTTTTGAAGAGGGCTGAGAATTC 400 
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3.2.8.3. Real-time quantitative PCR (qRT-PCR) analysis 
In general, two types of quantification strategies can be performed in qRT-PCR. The levels of 
expressed genes may be measured by an ‘absolute’ quantification or by a relative real-time 
qRT-PCR (Pfaffl, 2004). The ‘absolute’ quantification approach relates the PCR signal to a 
known input copy number, using a calibration curve (standard curve). Calibration curves can 
be derived from diluted PCR products, recombinant DNA or RNA or linearized plasmids. The 
reliability of such an absolute real-time RT-PCR assay depends on the condition of ‘identical’ 
amplification efficiencies for both the native mRNA target and the target RNA or DNA used 




Before running real time PCR analysis, the samples were further diluted 1:2 (in addition to 1:4 dilution 
in part 3.2.7, cDNA synthesis) with dH2O. These samples were placed on ice and a Master mixture 
was made according to table 15. Appendix 1 listed various amounts of primers and probes used in this 
thesis. 
Table 15. Mastermix table for real time PCR 
Reagents á μL x 80 μL 
2X Mastermix 10 800 
Forward primer X       these volumes were  80 x X   volumes subsequently 
Reverse primer Y      adjusted according to  80 x Y   adjusted to the 
Probe Z       concentration such that  80 x Z   column to the left. 
dH2O Δ       they made up 6 μL 80 x Δ 
 16 μL μL 
 
The real-time PCR reactions were performed on a clear 96-well plate (MicroAmp™ Fast Optical 96-
well Reaction Plate with Barcode (0.1 mL), Applied Biosystems, Foster city, CA, USA) using 
adhesive seal as cover. 16 µL mastermix was added into each well reserved for sample, standards or 
control, and 4 µL of each sample was added into sample-wells, in duplicate, while standards were run 
in triplicate. For water sample (negative control), 16 µL of mastermix and 4 µL of dH2O were added 
into a separate well on the sample plate. The whole plate was quickly centrifuged (11 s) and run on a 
real time PCR instrument (7900 HT Fast Real-Time PCR system, Applied Biosystems). Samples were 
heated for 20 s at 95°C and then subjected to 40 cycles of denaturation at 95°C for 1 s and annealing 
and elongation at 60°C for 20 s. In addition to negative control, no amplification control (RT- minus) 
was included in every assay. 
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3.2.8.4. Relative gene expression 
Relative quantification measures the relative change in mRNA expression levels. It 
determines the changes in steady state mRNA levels of a gene across multiple samples and 
expresses it relative to the levels of another RNA. Relative quantification does not require a 
calibration curve or standards with known concentrations and the reference can be any 
transcript, as long as its sequence is known (invited review, Bustin, 2002). The units used to 
express relative quantities are irrelevant (Pfaffl, 2006).  
 
To achieve optimal relative expression results, appropriate normalization strategies are 
required to control for experimental error. A control gene/ reference gene that is expressed at 
a constant level is used to normalize the gene expression results for variable template amount 
or template quality and to control the cDNA synthesis. Reference genes are the most common 
method for normalizing qRT-PCR data. This strategy targets RNAs that are universally and 
constitutively expressed, and whose expression does not differ between the experimental and 
control groups, to report any variation that occurs due to experimental error. The relative 
expression of a target gene to another gene, mostly a reference gene, can be calculated on the 
basis of “delta Ct“(ΔCt, normalization to a reference gene) and “delta delta Ct” (ΔΔ Ct, 
normalization to control sample) values, with following equation 
 
                                     2[Ct cyclophilin A – Ct target gene]        Treated sample 
                                                                          R =                                                                                        .      
                                     2[Ct cyclophilin A – Ct target gene]        Control sample 
 
Procedure 
In this study, the relative expression of each target genes were quantified by first normalizing to the 
reference gene (cyclophilin A, ΔCt) and then to the control samples (ΔΔCt). 
 
3.2.9. FLOW CYTOMETRY 
Flow cytometer is an instrument that illuminates cells (or other particles) as they flow 
individually in front of a light source and then detects and correlates the signals from those 
cells that result from the illumination (Givan, 2004). Each particle will scatter the emitted 
light, and this scattered light can be detected and stored in a data file for subsequent analysis. 
In most cases, particles without background (auto-) fluorescence have to be stained with 
fluorescent dyes or fluorophores during preparation to make non-fluorescent compounds 
“visible” to the cytometer. The fluorescent dyes can be conjugated to antibodies, and then the 
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fluorescence from a cell will be a readout for the amount of protein/ antigen (on cell surface/ 
in cytoplasm or nucleus), to which the antibody has bound to. 
 
Procedure 
The fragminized blood was distributed to three wells in a 6-wells plate, so that each contained 2 mL of 
blood. Three different samples were studied: 
1. Controls: blood with vehicle control (saline) 
2. LPS-stimulated samples 
3. Samples stimulated with LPS+PAF 
Both LPS and PAF were diluted from stock preparations using a serial dilution by using sterile saline 
to a final concentration of 5 ng/ mL and 10 μM in blood, respectively. The samples were incubated for 
two hours at 37°C in a 5% CO2 atmosphere under constant rotation. 
Table 16. Setup for flow cytometry experiments. 
Well no Incubation at 37°C for 120 min. 
1 1980 μL blood + 20 μL saline 
2 1980 μL blood + 20 μL LPS (final: 5 ng/ mL) 
3 1976 μL blood + 4 μL PAF (final: 10 μM) + 20 μL LPS (final: 5 ng/ mL) 
 
After two hours of incubation, 100 μL aliquots were taken from each well, as shown in table 17 below. 
 
Table 17. Aliquots and antibodies preparation. 
Well no Stimulation 100 μL aliquots μL antibody added 
Unstained  
CD14 – APC 5 
CD16 – PE 5 
CD62P (P-sel) – FITC 10 
CD42a – FITC 10 




CD14 + CD16 + CD42a 5 + 5 + 10 
CD14 + CD16 + CD62P 5 + 5 + 10 2 LPS 
CD14 + CD16 + CD42a 5 + 5 + 10 
3 LPS+PAF CD14 + CD16 + CD62P 
CD14 + CD16 + CD42a 
5 + 5 + 10 
5 + 5 + 10 
 
For well number 1, seven 100 μL aliquots were made, while two aliquots á 100 μL were prepared for 
each of well number 2 and 3, TT tubes were used in this step.  
 
Antibodies. The following murine monoclonal antibodies from BD Biosciences, USA and Serotec, 
UK, were used: allophycocyanin (APC)-conjugated anti-CD14 (5 μL per test) to identify monocytes, 
granulocytes were identified by using phycoerythrein (PE)-conjugated anti-CD16 (5 μL per test), 
fluorescein isothiocyanate (FITC)-conjugated anti-CD62P (10 μL per test) to identify expression of  
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P- selectin and FITC-conjugated anti-CD42a (10 μL per test) to identify the (glycoprotein) gpIX part 
of the gpIb-IX complex found on the human platelets. 
 
Table 18. Antibodies for flow cytometric analysis. 
Antibody Specificity Supplier Conjugate 
Anti-CD14 Monocytes marker BD Biosciences, San Jose, Ca, USA APC 
Anti-CD16 Granulocytes marker 
(also on 5-10% 
monocytes) 
BD Biosciences PharMingen PE 
Anti-CD62P P-selectin, α-granule 
marker 
BD Biosciences PharMingen FITC 
Anti-CD42a gpIX part of the vWf 
receptor complex on 
human platelets 
Serotec, UK FITC 
 
Preparation of whole blood samples for flow cytometry. The 100 microliter aliquots were taken as 
shown in table 17. The aliquots were incubated with antibodies for 30 min. in the dark. Four of the 
samples were incubated with only one antibody while for the rest in three antibodies (volume added as 
given above) were used combination. One aliquot was left unstained and incubated without any 
antibody. After incubation, two milliliters of FACS lysis solution mix was added to each tube, for lysis 
of red blood cells, and incubated at room temperature in the dark for 11 minutes. All the tubes were so 
spun down at 1450 x g for 10 min. The resulted supernatant was removed and the tubes were washed 
once by filling with PBS and spun down at 1450 x g for 10 min. The supernatant was removed and the 
pellet dissolved in 400 μL PBS. The tubes were placed on ice and protected from light until flow 
cytometric analysis could be performed.   
 
3.2.9.1. Flow cytometric analysis 
All information that a flow cytometer reveals about a cell comes from the time when cell is 
passing through the laser beam. The intersection point between the laser beam and the flowing 
cells is called the “analysis point” or “interrogation point”. The flow cytometer used in this 
thesis is a FACSAriaTM Cell Sorter from BD Biosciences. The cells are analysed as they 
travel one by one in a moving fluid stream past fixed focused laser beam from a built-in, air-
cooled, Coherent Sapphire solid state laser and He-Ne laser, and an optional violet diode laser. 
The laser light is scattered in all directions as the cell passes through a laser beam. The 
scattered light that is measured at 0.7° to 10° is called forward scatter and at about 90° side 
scatter. Up to twelve parameters can be measured for each cell: forward scatter light (FSC), 
side scatter light (SSC) and an octagon containing six photomultiplier tubes (PMTs) and two 
trigons containing two PMTs each. These characteristics, pertaining to how the cell scatters 
the laser light and emits the fluorescence, provide the information about the cell size (FSC), 
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internal complexity or granularity (SSC), and relative fluorescence intensity. This information 
is collected and transmitted to a computer. 
 
Procedure 
The samples were immediately analyzed after preparation, in a FACSAriaTM flow cytometer equipped 
with the FACSDiVa digital data system and software (BD Biosciences). The fluorescence intensity 
was controlled daily with the FACSDiVa according to the manufacturer’s instructions. The 
fluorescence compensation was manually adjusted with unstained whole blood, whole blood labeled 
with FITC-conjugated anti-CD62P (and anti-CD42a), whole blood labeled with PE-conjugated anti-
CD16 and whole blood labeled with APC-conjugated anti-CD14. Light scatter and fluorescence data 
were obtained with gain settings in the logarithmic mode from calculated events collected from each 
sample. The saved files were then exported from the flow cytometer data system and imported into 
another FACSDiVa data system software for analyzing. 
Leukocyte subpopulations, especially granulocytes, monocytes (and lymphocytes), and the population 
of platelets were identified by means of their light scatter characteristics, enclosed in electronic gates 
and separately analyzed for fluorescence intensity from different bound fluorochrome-labeled 
antibodies, Figure 8.  
















Materials and Methods 
Figure 8. Platelet-monocyte aggregates in whole blood analysis by flow cytometry. A. A plot of 
FSC vs. SSC characteristics from cells obtained from hemolysed whole blood indicates that regions 
can be drawn around cells with different scatter characteristics. Distinct populations of granulocytes 
(purple), monocytes (green), lymphocytes (black) and platelets (blue), are separated by gating. Cell 
populations were determined by immunostaining of whole blood with PE-conjugated anti-CD16 (a 
marker of granulocytes, purple), monocytes were labelled with CD14-APC and platelets with CD42a-
FITC and defined by the MFI values during flow cytometrical analysis. B. A histogram was created 
over the gated CD14-bright monocytes population. The monocytefraction contains approximately 90% 
CD14-positive (CD14+) cells. Upon gating to P6, 100% CD14+ is observed. C. Granulocytefraction 
from the scatterplot contains nearly 100% CD16+ cells. Narrowing the population by gating to P2 
resulted into 100% CD16+. D. A plot of CD14-bright monocytes against CD42a was used to 
determine the amount of monocytes positive for CD42a (platelet-monocyte aggregates). The platelets 
were not further gated but calculated directly from platelet population as gated in the scatterplot graph. 
FSC = forward scatter, SSC = side scatter, APC = allophycocyanin, PE = phycoerythrin,  







3.3. Statistical analysis 
Results are reported as mean ± SEM, however, the flow cytometry results were expressed as 
median. Statistical analyses were performed using the SPSS 15. Paired-samples t-test was 





4.1. Time course of TF activity in response to LPS stimulation  
Since the purpose of this thesis was based on previous results obtained when studying the 
effects of aspirin and prostaglandin E2 upon LPS-induced TF activity, a characterization of 
the time effects of the LPS-stimulation of whole blood was performed. As shown in Figure 9, 
maximum TF activity in response to LPS stimulation peaked between 1.5 and 4 hours of 
incubation, however adjusting for controls TF activity peaked at 2 h (see table 19). As 
expected, samples stimulated with LPS showed a much higher TF activity when compared 
with non-stimulated control. TF activity was 1.8-fold higher in the 2 h incubated LPS-
stimulated samples compared to 1.5 h (p<0.05), however when adjusted for background TF 
activity, there were no significant differences between the 1.5 h, 2 h and 4 h time points. 
 




























































Figure 9. LPS time response – effects on TF activity. Whole blood was stimulated with LPS for the 
indicated incubation time. Saline was used as control samples. * p <0.05 vs. saline-incubated,  





Table 19. LPS time response – effects on TF activity. LPS- stimulated samples. 
Time (h) TF activity (mU/106 mnc) (mean 
± SEM) 
TF activity fold induction vs. 
saline control 
0 0.11 ± 0.01 1.00 ± 0.38 
0.5 0.13 ± 0.07 1.44 ± 1.47 
1 1.47 ± 0.24 12.19 ± 5.05 
1.5 2.53 ± 0.37 12.01 ± 6.45 
2 4.60 ± 0.58 17.21 ± 8.22 
4 5.90 ± 2.37 8.18 ± 2.30 










4.2. Time course of individual gene expression in response to LPS stimulation 
The resulted mRNA expression is relative to zero hour and normalized to the reference gene 
cyclophilin A. Cyclophilin A has previously been demonstrated to be the most stably 



















TF mRNA expression is shown in Figure 10, and table 20 (LPS-stimulated values). 
Maximum TF mRNA expression was observed between 1 h to 2 h. Between 2 h and 4 h a 
significant reduction (-56%, p<0.05) in LPS-induced TF mRNA was evident. Further 
incubation reduced the TF mRNA event more and this was paralleled by an increase in 
background TF mRNA levels. This indicates that whole blood samples are gradually activated 
without any added stimulation during prolonged incubation.  
 
















































Figure 10. Tissue factor mRNA expression. Stimulated samples were incubated with 5 ng/ mL LPS. 
Whole blood incubated with saline was used as control. * p<0.05 vs. saline-incubated.  
† p<0.05 vs. LPS-stimulated 0.5 h, ‡ p<0.05 vs. LPS-stimulated 4 h. Paired-samples t-test. n = 3. 
 
Table 20. Tissue factor mRNA expression. LPS-stimulated samples. 
Incubation time (h) Tissue factor relative mRNA expression 
0   1.0 ± 0 
0.5  61.3 ± 21.1  
1  491 ± 78.2 
1.5  498± 81.1 
2  434 ± 98.3 
4  191 ± 67.4 
8 35.1 ± 2.4 









TNF-α mRNA expression is shown in Figure 11 and table 21 (LPS-stimulated values). In 
response to LPS, monocytes release the pleiotropic cytokine TNF-α. The TNF-α expression is 
extremely rapidly activated and maximum TNF-α is evident as early as 30 min after addition 
of LPS to the samples. The TNF-α mRNA concentration stays at this level until 2 h after LPS, 
whereas the background TNF-α mRNA levels gradually increases (not significantly). 
Between 4 h and 8 h stimulation, the expression decreased with approximately 68% (p<0.05). 
 


















































Figure 11. TNF-α mRNA expression. The figure shows mRNA levels for both LPS-stimulated and 
control (saline) samples. * p<0.05 vs. saline-incubated. † p<0.05 vs. LPS-stimulated 8 h. Paired-
samples t-test. n = 3. 
 
 
Table 21. TNF-α mRNA expression. LPS- stimulated samples. 
Incubation time (h) TNF-α relative mRNA expression 
0  1 ± 0 
0.5 60.50 ± 10.7 
1  63 ± 7.4 
1.5  50.8 ± 6.4 
2  51 ± 4.8 
4  53.7 ± 4.8 
8  17.1 ± 2.3 






LPS-induced IL-1 beta mRNA expression was found to peak around 1.5 h and 2 h 
stimulation, although not significant, there is nearly 3% increment with half an hour longer 
incubation between these time points. The background (saline controls) IL-1β levels were 
very low compared to the levels obtained by LPS-stimulation (7-fold induction for 1.5 h, 
p<0.05, 5-fold for 2 h). 
 










































































   
Figure 12. IL-1β mRNA expression. Fragminized whole blood stimulated with 5 ng/ mL LPS 
incubated as indicated. Saline samples were used as control. * p<0.05 vs. saline-incubated.  
† p<0.05 vs. LPS-stimulated 0 h. Paired-samples t-test. n = 3. 
 
 
Table 22. IL-1 beta mRNA expression. LPS- stimulated samples. 
Incubation time (h) IL-1 beta relative mRNA expression 
0 1 ± 0 
0.5 46.3 ± 6.5 
1 243.5 ± 37.5 
1.5 309.3 ± 48.3 
2 318.5 ± 67.7 
4 131 ± 32.8 
8 38.0 ± 4.2 





Figure 13 shows that a biphasic effect is observed for IL-8 mRNA expression in LPS-
stimulated whole blood. Also IL-8 has a primary peak observed after 1.5-2 h of LPS- 
stimulation, however, a secondary peak is observed after prolonged incubation. This 
secondary production of IL-8 mRNA is a result of increased levels of TNF-α (and other 
cytokines such as IL-6) which also will stimulate synthesis of IL-8 in the stimulated blood. It 
is also important to note that IL-8 is a sensitive marker which tells a lot about the activation 
state of the samples, and it can be observed from the figure that the background levels for IL-
8 mRNA increased a lot after 1-2 h incubation. The mRNA levels reached after 12 h LPS-
stimulation is not significantly higher compared to the levels obtained in the first peak (1.5 h 
or 2 h). It is further observed that there is a significant increment, approximately 94%, for 
stimulated samples incubated from 1 to 1.5 h (p<0.05), LPS-stimulated and saline-incubated 
samples also show obvious differences at this incubation period (p<0.05). 













































































































Figure 13. IL-8 mRNA expression. Figure shows the bi-phased gene expression of IL-8 for samples 
stimulated with LPS. Samples incubated with saline were used as control. * p<0.05 vs. saline-
incubated, † p<0.05 vs. LPS-stimulated 0.5 h, ‡ p<0.05 vs. LPS-stimulated 1 h.  










Table 23. IL-8 mRNA expression. LPS- stimulated samples. 
Incubation time (h) IL-8 relative mRNA expression 
0 1 ± 0 
0.5 33.4 ± 8.5 
1 202.8 ± 18.5 
1.5 393.7 ± 43.9 
2 403 ± 88.2 
4 247.8 ± 47.60 
8 582.3 ± 162.50 






MCP-1 mRNA expression is shown in Figure 14. The LPS-induced MCP-1 expression 
peaked at 8 h at an mRNA level 35-fold higher when compared to 1.5 h, but this effect was 
not significant. It is important to consider the enormous background-induced expression of 
MCP-1 mRNA. 
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Figure 14. MCP-1 mRNA expression. 5 ng/ mL LPS was added to whole blood and incubated as 







Table 24. MCP-1 mRNA expression. LPS- stimulated samples. 
Incubation time (h) MCP-1 relative mRNA expression 
0 1 ± 0 
0.5 3.1 ± 0.6 
1 4.8 ± 0.95 
1.5 45.9 ± 24.2 
2 67.0 ± 15.9 
4 1045.1 ± 326.5 
8 1603 ± 478.0 
12 806.5 ± 275.0 
 
 
Summary of the LPS-induce time responses. The time response study is an indication on 
how long samples should be incubated. It is observed that incubation around 1.5 h to 2 h 
should be sufficient for further work. 































Time (hours)  
Figure 15. Summary of the LPS-induced time responses. In the figure, the relative mRNA levels 
are normalized to the reference gene and related to the mRNA expression in the saline controls. As 






4.3. Manipulation of prostaglandin metabolism – effects on monocyte TF 
activity in whole blood   
We analyzed the effect of manipulation of the prostaglandin metabolism by inhibiting single 
enzymes involved in the prostaglandin synthesis, COX-1, COX-2, and mPGES. The tissue 
factor activity after treatment with different inhibitors is shown in table 25 below. The COX-1 
inhibitors (SC-560 and aspirin) did not significantly influence the LPS-induced TF activity in 
our experiments. However, there was a trend for enhancement of the LPS-induced TF activity 
for both of these inhibitors. This effect was quite pronounced in the highest LPS responders, 
whereas there was no effect of the COX-1 inhibitors in the individuals with the lowest 
inducing effect from LPS. Treatment with the more specific prostaglandin synthesis inhibitors, 
CAY10526, also resulted in an insignificant trend for enhanced TF activity, whereas the 
specific prostaglandin E synthase (mPGES) inhibitor MF63, resulted in a significant 
enhancement of the LPS-induced TF activity (0.2 μM MF63, +41%, p<0.05 and 20 μM MF63, 
+107%, p<0.05). Also the specific COX-2 inhibitor CAY10404 had no significant effect on 
the TF activity. However, the trend was towards an enhancement of the activity. To 
investigate the link over to the leukotrienes pathways, a dual COX-2/ 5-LOX inhibitor 
(CAY10416) was tested. This compound did not result in any significant effects, however 

















Table 25. The effects of manipulating the prostaglandin metabolism on TF activity. Samples were 
pre-incubated with different doses of the inhibitors, and subsequently stimulated with 5 ng/ mL LPS.  
* p<0.05 vs. vehicle control. Paired-samples t-test. n = 6, ªn = 4. Values are mean ± SEM. 
 
 
Sample Target TF activity 
(mU/106) 
LPS/ Vehicle control (DMSO:saline 
(1:10)) 
 5.30 ± 1.34 
 
 
Aspirin, 2 μM + LPS COX-1 (COX-2) 6.54 ± 1.97 
Aspirin, 20 μM + LPS COX-1 (COX-2) 8.50 ± 3.38 
Aspirin, 200 μM + LPS COX-1 (COX-2) 8.92 ± 4.65 
 
SC-560, 50 nM + LPS COX-1, selective 7.30 ± 2.81 
SC-560, 500 nM + LPS COX-1, selective 8.98 ± 2.86 
SC-560, 5 μM + LPS COX-1, selective 6.84 ± 2.15 
 
CAY10404, 50 nM + LPS COX-2, selective 8.60 ± 2.74 
CAY10404, 500 nM + LPS COX-2, selective 6.97 ± 2.03 
CAY10404, 5 μM + LPS COX-2, selective 9.48 ± 3.37 
 
CAY10526, 100 nM + LPS Inhibits PGE2 synthesis 6.72 ± 1.67 
CAY10526, 1 μM + LPS Inhibits PGE2 synthesis 10.18 ± 3.35 
CAY10526, 10 μM + LPS Inhibits PGE2 synthesis 6.82 ± 2.55 
 
MF63, 0.2 μM + LPS mPGES 7.48 ± 2.07* 
MF63, 2 μM + LPS mPGES 8.63 ± 2.25 
MF63, 20 μM + LPS mPGES 10.95 ± 3.23* 
 
LPS/ Vehicle control (DMSO:saline 
(1:10)) 
 19.65±8.49 
CAY10416, 50 nM + LPS COX-2/5-LOX 16.45 ± 4.37ª 
CAY10416, 500 nM + LPS COX-2/5-LOX 19.95 ± 6.14ª 
CAY10416, 5 μM + LPS COX-2/5-LOX 15.58 ± 3.94ª 
 
 
4.4. Manipulation of prostaglandin metabolism, eicosanoid inhibition studies – 
effects on individual cytokine mRNA expression in response to LPS stimulation   
mRNA expression levels of the various cytokine samples are all normalized first to the 





4.4.1. Effect of aspirin on LPS-induced expression of proinflammatory genes in 
whole blood  
Whole blood samples incubated with aspirin is shown in Figure 16 below. In general, 
preincubation of the blood with aspirin prior to addition of LPS, resulted in enhanced mRNA 
expression of TF and the chosen cytokines. The effects of aspirin are similar for all the genes 
analyzed. For both IL-1β and IL-8, preincubation with aspirin resulted in a significant 
enhancement of the mRNA expression, whereas for TF and MCP-1, the enhancing effects 
were not significant. For IL-8, all doses of aspirin resulted in significant increase in mRNA 
expression, varying from 67% to 78% enhancement for 20 μM and 200 μM, respectively. The 
lowest dose resulted in over 100% enhancement of the mRNA expression for this cytokine. A 
very similar aspirin response was observed for IL-1β. But for this cytokine only the lowest 
aspirin-dose reached significant levels (+86%, p<0.05). 
For TNF-α, the aspirin response was less pronounced compared to IL-8 and IL-1β and the 
response was significant only for the 200 μM concentration (+36%, p<0.05). 
For tissue factor mRNA expression, the aspirin seemed to have an enhancing effect, however 
this was not significant for any aspirin concentration. This was also the case when analyzing 
the aspirin effect on LPS-induced MCP-1 expression. Note that only 2 individuals were used 
for the MCP-1 mRNA expression analyses, and if the numbers had been increased also  
MCP-1 would have become significant.  































Figure 16. Aspirin as COX-1/2 inhibitor. Whole blood samples were first preincubated with various 
doses of the inhibitor, then stimulated with LPS for 90 min. Vehicle sample (DMSO and saline) was 
stimulated with LPS. * p<0.05 vs. vehicle sample. Paired-samples t-test. n = 6, n = 2 (MCP-1). 
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Results 
4.4.2. The effect of the selective COX-1 inhibitor SC-560 on LPS-induced 
expression of proinflammatory genes  
As aspirin, also the COX-1 inhibitor SC-560, generally increased whole blood cytokine 
mRNA expression in response to LPS. Furthermore, like aspirin, the most pronounced effects 
of SC-560 were observed for IL-8 and IL-1β, but TF mRNA was also enhanced by this 
inhibitor. And for both cytokines a pronounced effect were observed for the lowest inhibitor 
concentration, on the other hand, a significant enhancement of the LPS-induced cytokine 
mRNA expression were evident (+37% and 38%, respectively, for IL-1β and IL-8). For TNF-
α mRNA expression, the effect of SC-560 was less pronounced when compared to aspirin, 
and no significant effect was observed for this cytokine. SC-560 increased the LPS-induced 
MCP-1 expression levels, however due to the low parallels (n), this effect was not significant.  
 





























Figure 17. Selective COX-1 inhibitor on cytokines gene expressions. Whole blood samples were 
first preincubated with various doses of the inhibitor, then stimulated with LPS for 90 min. Vehicle 
sample (DMSO and saline) was stimulated with LPS. * p<0.05 vs. vehicle sample.  











4.4.3. The effect of the selective COX-2 inhibitor CAY10404 on LPS-induced 
expression of proinflammatory genes  
The effects of the inhibition of the inducible COX-2, was not as pronounced as inhibition of 
COX-1, however also CAY10404 resulted in enhancement of the LPS-induced expression of 
IL-8. For none of the other cytokines did the effects of the COX-2 inhibitor reach any 
significant levels. Contrary to the COX-1 inhibitors, the highest concentration seemed to 
cause a non-significant reduction in the mRNA expression for all cytokines except IL-8.  




























Figure 18. CAY10404 – selective COX-2 inhibitor.  Whole blood samples were first preincubated 
with various doses of the inhibitor, then stimulated with LPS for 90 min. Vehicle sample (DMSO and 
saline) was stimulated with LPS. * p<0.05 vs. CAY10404 5 μM, † p<0.05 vs. CAY10404 5 μM, ‡ 















4.4.4. The effect of prostaglandin synthesis inhibitor CAY10526 on LPS-induced 
expression of proinflammatory genes  
Inhibition of the prostaglandin synthesis using CAY10526 also resulted in a dose-related 
increase in cytokine mRNA expression in response to LPS. However, for TNF-α, IL-1β, and 
IL-8, this effect was most pronounced at the lower inhibitor concentrations whereas the effect 
was lower at higher inhibitor concentrations, and the highest concentration of CAY10526 did 
not have any significant effect for the cytokines tested. The strongest effect of the inhibitor 
was evident for IL-1β mRNA expression (apart from MCP-1: +80% MCP-1 mRNA 
expression using 100 nM inhibitor, n = 2, p<0.05) and the relative IL-1β mRNA levels were 
increased by 80% (p<0.05) and 90% (p<0.05) using inhibitor concentrations of 1 μM and 100 
nM, respectively. For TNF-α and IL-8, inhibition of the prostaglandin synthesis result in an 
enhancement of LPS-induced mRNA expression of +37% and + 73% (100 nM inhibitor, 
TNF-α and IL-8, respectively). The mPGES-1/ COX-2 inhibitor did not significantly 
influence LPS-induced TF mRNA expression.  






























Figure 19. mPGES-1/cox-2 inhibitor. Whole blood samples were first preincubated with various 
doses of the inhibitor, then stimulated with LPS for 90 min. Vehicle sample (DMSO and saline) was 









4.4.5. The effect of selective prostaglandin synthesis inhibitor MF63 on LPS-
induced expression of proinflammatory genes  
Samples with mPGES-1 inhibitor (MF63) show both augmentation and inhibiting effect of TF 
mRNA expression, where the highest doses resulted into an approximately 11% increase. A 
bi-phased expression is seen for nearly all the genes. It is further observed that the middle 
dose of the inhibitor seemed to induce gene expressions at a higher level than controls and 
other doses. 
Although not significant, high increases in expression of MCP-1 were also found for 
strongest- and weakest doses, in addition to the most pronounced effect of the middle dose.  
Similar effects were observed for TNF-α, IL-1β and IL-8 gene expression, but with a slightly 
weaker effect. 
 



























Figure 20. Selective mPGES-1 inhibitor. Samples were preincubated with the inhibitor then 
subsequent to LPS stimulation. Vehicle sample composed of DMSO and saline, then further 













4.5. Antibody identification of leukocyte subpopulations   
Leukocyte subpopulations (granulocytes and monocytes) interacting with platelets were 
examined using the FACSAria™. Differential countings for granulocyte-, monocyte- and 
platelet population were performed based on the FSC/SSC gating. PE-conjugated anti-CD16 
was used to identify the granulocyte population, APC-conjugated anti-CD14 address to the 
monocyte population, and identification of platelet population was done using FITC-
conjugated anti-CD42a. In whole blood samples stimulated with LPS, a significant increase 
was observed for the surface expression of the granulocyte- and monocyte markers CD16 and 
CD14 (p<0.05), as depicted in Figure 21. No further increase was observed in these markers 
when blood was stimulated with LPS and PAF in combination. The amount of the platelet 
specific marker CD42a did not change when blood was stimulated with either LPS alone or in 
























































Figure 21. Electronic gate based on the FSC/SSC gating separated the different leukocyte 
subpopulations and platelet population. Samples were run as non-stimulated, LPS-stimulated and 
stimulated with LPS and PAF in combination. Anti-CD16 marker for granulocyte-, anti-CD14 marker 
for monocyte- and anti-CD42a marker for platelet population. * p<0.05 vs. non-stimulated. 










4.5.1. Quantification of adherent platelets in leukocytes 
Platelet-leukocyte heteroconjugates were defined as monocytes positive for CD42a. Platelet 
(CD42a) interactions with monocyte increased (approximately 50%, not significant) upon 
LPS stimulation (Figure 22). Addition of PAF in addition to LPS to the samples further 
enhanced the conjugate formation and a 3-fold significant increase in platelet-monocyte 
aggregates were observed (p<0.05), when compared to LPS. Compared to the non-stimulated 
control samples, the increase after LPS+PAF stimulation was over 6-fold but not significant 
due to interindividual variance in the conjugate formation. 
Ex vivo LPS stimulation of fragminized whole blood demonstrated that the binding of platelet 
to granulocytes decreased when compared to non-stimulated samples. However, the platelet-
granulocyte aggregates slightly increased when stimulated with both LPS and PAF. 
 



















Figure 22. Platelet-leukocyte aggregates. Non-stimulated (saline)- and stimulated samples were 
incubated for 120 min. at 37°C, to prior flow cytometry preparation and analysis. * p<0.05 vs. LPS. 












It has been reported that platelet-leukocyte aggregates form mainly via platelet-expressed P-
selectin and its leukocyte receptors, PSGL-1 and CD15 (Lehr et al., 1994). The amount of P-
selectin associated with leukocytes was measured using anti-CD62P. When compared to non-
stimulated samples, CD62P associated with monocytes increased non-significantly after both 
LPS and LPS+PAF stimulation (+24% and 47.7%, respectively) (Figure 23). A marked 
decrease in P-selectin-granulocyte aggregates are seen for samples stimulated with LPS and 
PAF (-23%, p<0.05). 



















Figure 23. P-selectin (CD62P) associated with leukocyte subpopulations. Non-stimulated (saline)- 
and stimulated samples were incubated for 120 min. at 37°C, prior to flow cytometry preparation and 
analysis. * p<0.05 vs. non-stimulated. Paired-samples t-test. n = 4. 
 
The amount of platelets bound to the leukocyte subpopulations was quantified and compared 
with the total amount of platelets. As expected, most of the detected CD42a was found in the 
platelet population (Figure 24). Stimulation of the samples resulted in a small release of 
CD42a from the platelet surface. For the LPS-stimulated samples a minor non-significant 
reduction of CD42a present in the platelet window was observed (-2.5%), whereas samples 
stimulated with both LPS and PAF revealed a marked decrease of CD42a (-13.3%, p<0.05). 
When the relative amount of CD42a in the platelets window dropped, this part of the CD42a 
was found in the monocyte window. After stimulation with LPS and LPS and PAF in 
combination, an increase of monocyte associated CD42a of 3% and 13% (p<0.05), 
respectively, was seen. The percentage of CD42a associated with the granulocyte population 




































Figure 24. Localization of CD42a. Detected amount of the platelet marker CD42a in the platelet, 
monocyte and the granulocyte window. * p<0.05 vs. non-stimulated or LPS. 
 
The relative amount of CD62P (P-selectin) in the platelet, monocyte and granulocyte 
windows was also quantified. In the non-stimulated situation, the amount of CD62P 
associated with the monocytes and granulocytes (approximately 40% in both populations) 
were higher compared to the platelet surface associated CD62P (ca. 20%) (Figure 25). After 
stimulation with LPS and LPS+PAF, the relative amount of CD62P-positive granulocytes was 
reduced (-5% LPS-stimulated and -14% for LPS+PAF, p<0.05). The CD62P was slightly 
increased on both monocytes and platelets upon stimulation with both LPS and LPS in 
combination with PAF. For the platelets, the relative increase in CD62P-positive cells 




































Figure 25. Localization of CD62P. P-selectin is detected as CD62P-positive in various population.  




The whole blood system is a convenient test system, as it is readily available and reduces 
artifacts due to handling and isolation of cells. Furthermore, all the circulating blood 
components are present, and the different cell types are maintained at their in vivo state and 
may interact with each other. Since interindividual variations in blood cell number and blood 
component concentrations are preserved, experimental data might have a large variation, 
which is also useful in a clinical setting. 
 
The results obtained from TF activity measurement, real-time PCR analysis and flow 
cytometry indicated that the applied methods were suitable to carry out the objectives of this 
study. The flow cytometry procedure showed that rapid information on platelet-leukoycte 
conjugate formation in whole blood can be obtained. However, improvement of the results 
would be to include a higher number of test persons. 
 
5.1. Time course in response to LPS-stimulation 
The time course TF activity in response to LPS-stimulation has previously been investigated 
in a study examining how different anticoagulants (EDTA, citrate, heparin, hirudin) modify 
blood cell behavior (Engstad et al., 1997). When hirudin or heparin was used as 
anticoagulants a peak was reached after two hours of incubation. After a transient drop in 
activity it further increases up to 6 h. It was further observed that there was significantly 
increase from 1 to 2 h of incubation. In our study, LPS-induced TF activity increased up to a 
plateau level reached at 2 h. No significant increase was obtained when incubating the blood 
for 4 h, and at 8 h the LPS response had started to drop. At 4 h stimulation there was a huge 
interindividual variation in our study as the activity was very high in some individuals and 
had started to drop in other individuals. Increasing the incubation time from 1.5 h (and 1 h) to 
2 h resulted in a significant enhancement of the LPS-induced TF activity. The observation that 
TF activity decreased after reaching the peak has also been observed in previously studies of 
Østerud’s group (Østerud, personal communication). This indicates that it takes several hours 




For the TF activity to increase significantly, the blood cells have to synthesize more of the TF 
protein. In addition, it has been indicated that potential (intracellular) pools of encrypted TF 
may be decrypted (or made bioavailable) in a process involving platelets (Østerud, 2001). 
When using isolated peripheral blood monocytes or adherent monocytes, other authors have 
indicated that TF activity reaches maximum after 3 h (Ramani et al., 1993), 7 h (van der Logt 
et al., 1994) and 10 h (Meszaros et al., 1994). These observations demonstrate how different 
monocytes behave when they are isolated, extensively manipulated, and deprived for their 
natural environment. In addition, an adequate LPS response towards low-concentration LPS, 
as used in our study, is dependent of the presence of soluble serum proteins such as CD14 and 
LPS-binding protein to function optimally (Meszaros et al., 1994). 
 
In our study, the LPS concentration used (5 ng/ mL), was in agreement with Engstad et al. 
(1997). The LPS response also varied between batches and this is routinely checked in our 
laboratory. Using higher LPS concentrations also result in a completely different situation as 
the soluble plasma proteins no longer are necessary to present LPS to toll-like receptor 4, the 
cellular receptor which mediates the LPS-response. 
 
The mRNA expression is generally more rapidly compared with the protein synthesis 
dependent TF activity, and TNF-α gene expression was observed to reach its maximum 
plateau level as quickly as half an hour after the addition of LPS. This rapid increase in the 
mRNA levels indicates that the cells are quickly signaled to begin transcribing the TNF-α 
gene. This observation is consistent with studies using human whole blood and murine 
macrophages of (Dedrick & Conlon, 1995) and DeFranco’s group (Weinstein et al., 1991), 
respectively. In our study, TNF-α mRNA levels remained high for several hours (>4 h).  
TF mRNA expression had a later onset compared to TNF-α mRNA, and maximum TF mRNA 
expression was observed after 1 h stimulation. TF mRNA expression seemed to decline more 
rapidly compared to TNF-α, as TF mRNA levels had started to drop after 4 h stimulation. Yet, 
the kinetics of the TF mRNA expression seems to correspond well with the observed kinetics 
for LPS-induced TF activity. 
 
The expression of IL-1β followed very similar kinetic pattern as TF mRNA expression. This 
might indicate that they have common properties as LPS-induced inflammatory genes in 
monocytes. The work of (Dedrick & Conlon, 1995) demonstrated that the TNF-α mRNA 
levels declined after 60 min, with the concentration used of LPS 1 ng/ mL, the expression was 
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Discussion 
maintained only if more LPS was added, so it is speculated that the declining of expression is 
caused by the weakening of the LPS concentration. In addition, LPS-induced genes, such as 
TNF-α, IL-1β and TF, quickly degrade once the transcription is stopped due to their very 
unstable mRNAs (Taniguchi, 1988). Furthermore, Zuckerman and colleagues showed that 
prolonged stimulation by LPS for at least 6 to 8 h, causes tolerance towards LPS, leading to 
reduced ability to induce cytokine synthesis both in vivo and in vitro (Zuckerman et al., 1989). 
In our studies it is probable that the low LPS levels used will be neutralized during the first 
hours of incubation time, otherwise one might speculate that since our experiments were 
carried out up to twelve hours, tolerance might have an effect on the results. It is worth noting 
that the amount of LPS used will have an influence on the results. However, our study used a 
concentration of 5 ng/ mL, which is low-to-normal level in the whole blood system. Since 
binding and internalization of LPS by monocytes are greatly affected by the LPS 
concentration, these results might indicate that that expression of genes requires a cell to 
accumulate a critical amount of LPS (Gallay et al., 1993). 
 
A bi-phased expression was observed for IL-8 mRNA. This observation is also consistent 
with the study of DeForge and Remick in 1991 (DeForge & Remick, 1991). This complex 
pattern of the gene expression may be explained by that the stimulus for IL-8 release provided 
by LPS itself is self-limiting, and the early mediators such as TNF and IL-1 released by LPS 
stimulation, serves as a prolonged signal further enhancing IL-8 mRNA expression (DeForge 
et al., 1992). The IL-8 release in turn can attract neutrophils and lymphocytes to tissue site of 
inflammation. Activated platelets may also induce IL-8 mRNA expression in this whole blood 
model (Weyrich et al., 1996). 
 
In our experiments, MCP-1 mRNA expression was observed to be late, and the maximum 
expression was observed at 8 h of incubation. However, at this time point also saline started to 
induce MCP-1 mRNA expression. When adjusting for the background MCP-1 expression, the 
optimal incubation time seemed to be 4 hours for analyzing MCP-1 mRNA expression. And it 
seems obvious that MCP-1 mRNA expression analyzed after 1.5-2 h LPS stimulation is not 
the optimal conditions. Studies of Weyrich et al. on activated platelets with ELISA observed 
that monocytes did not release MCP-1 under basal conditions, and when monocytes were 
incubated without stimulation, little or no secretion of MCP-1 was seen (Weyrich et al., 1996). 
However, Weyrich et al. observed that addition of activated platelets (or RANTES (regulated 
upon activation normal T cell expressed presumed secreted) released from activated platelets) 
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to monocyte induce expression of MCP-1 and this may explain why we observed the MCP-1 
mRNA also started to accumulate in the saline controls after 8-12 h of incubation as this 
might cause some activation of the platelets (Weyrich et al., 1996). 
5.2. Eicosanoids inhibition studies 
Aspirin – COX-1/2 inhibitor. Pretreatment of human blood ex vivo with various doses of 
aspirin were shown to result in a dose-related enhancement (not significant) of LPS-induced 
TF activity. In agreement with this observation, a trend for enhanced LPS-induced gene 
expression of all the proinflammatory genes under investigation was demonstrated after 
pretreatment with aspirin. However, this enhancing effect was significant only for IL-8, IL-1β 
and TNF-α. These observations confirm a previous study demonstrating that ex vivo LPS-
induced TF activity was increased when healthy volunteers took 300 mg of aspirin 1 h before 
blood donation (Østerud et al., 1992). 
 
In low concentration aspirin only inhibits COX-1, however when higher doses are used 
aspirin will inhibit the inducible COX-2 as well. Aspirin is 170-fold more potent in inhibiting 
COX-1 than COX-2 (Vane et al., 1998). It has previously been demonstrated that 
exogenously added PGE2 inhibits LPS-induced TF activity (Østerud et al., 1992), which may 
indicate that inhibition of PGE2 synthesis should enhance LPS-induced TF activity. 
Matsumoto et al. (1997) reported that when arachidonic acid was added to resting rat 
peritoneal macrophages, TxA2 was produced immediately by COX-1, while production of 
PGE2 was delayed and dependent on the induction of COX-2. After COX-2 had been induced 
by LPS, exogenously added arachidonate resulted in no additional TxA2 synthesis, but large 
stimulation of PGE2 synthesis (Matsumoto et al., 1997). It is difficult to speculate about how 
this situation is when COX-1 is inhibited by aspirin, but it has been demonstrated that aspirin 
inhibits both TxA2 and PGE2 synthesis in LPS-stimulated whole blood (Østerud et al., 1992). 
Alternatively, when the cyclooxygenase pathway is inhibited by aspirin, more arachidonic 
acid becomes available as a substrate for the lipooxygenase pathway which is known to 
contribute to the LPS-induced expression of proinflammatory responses (Eilertsen et al., 
2003). 
 
Furthermore, the optimal dosage of aspirin for complete inhibition of platelet aggregation is 
subject to great interindividual variability and we also observed that the aspirin-effect was 
absent in some individuals whereas it was very pronounced in others. 
 63
Discussion 
Aspirin irreversibly inhibits the constitutive platelet COX-1, thus the platelet production of 
thromboxane and PGE2 is reduced. Østerud et al. further demonstrated that activity in 
monocytes without LPS-stimulated decreased after aspirin addition. This is an indication of a 
different activation mechanism when LPS is not the stimulating agent (Østerud et al., 1992). 
 
Selective COX-2 and COX-1 inhibitors. The present study demonstrates that CAY10404, a 
selective COX-2 inhibitor (coxib), does not significantly affect LPS-induced TF activity, or 
LPS-induced TF mRNA expression. However, at 5 μM CAY10404, a trend for reduction of 
mRNA expression for all the investigated genes, except IL-1 was observed. In fact, lower 
concentrations of the coxib caused enhanced expression of both IL-8 and IL-1β. The 
concentrations of the coxib used in our study are all above the IC50 for inhibition of COX-2, 
which is <1 nM in isolated cells. 
 
Free arachidonic acid activated cyclooxygenase and lipooxygenase in platelets. When the 
COX-2 inhibitor was added, an inhibition of cyclooxygenase pathway occurred. Since 
lipoxyenase is not inhibited, the oxygenation of liberated arachidonate should continue until 
no arachidonate is longer available (Hamberg & Hamberg, 1980). 
Furthermore, the treatment with COX-2 inhibitor enhanced the effect on TF activity 
generation, which indicate that the lipooxygenase, and not cyclooxygenase pathway, was 
involved in the generation of TF activity. 
 
COX-2 is inducible by proinflammatory stimuli, including cytokines and endotoxin, and is 
hence considered to be responsible for proinflammatory prostaglandin formation. The 
addition of COX-2 inhibitor does not only reduce the synthesis of PGE2, but may redirect free 
arachidonate into the lipooxygenase pathway, thus enhancing the leukotrienes generation 
(Brock et al., 1999; Østerud et al., 1992). LTB4 is known to enhance LPS-induced IL-8 
release from blood cells (Lund & Østerud, 2003). Similar explanation can be accounted for 
the increased IL-8 expression when samples were incubated with the selective COX-1 
inhibitor. 
 
After LPS stimulation, TNF-α is the first cytokine to be detected in the circulation, thereafter 
IL-1 is observed (DeForge et al., 1992). The TNF-α expression decreased as the coxib was 
added to samples, while IL-1β expression increased as lower doses were used. In contrast to 
this observation, in whole blood culture, selective COX-2 inhibition was found to increase the 
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TNF-α production, detected by ELISA ((Härtel et al., 2004). Moreover, at the highest 
concentration of 50 μM, TNF-α production increased to 153.9% as compared to stimulated 
cells incubated without COX-2 inhibitor (Härtel et al., 2004). This discrepancy might be 
explained by that PGE2 has cellular actions which can be considered both pro-inflammatory 
and anti-inflammatory. Via anti-inflammatory, it suppresses monocyte TNF-α and IL-1β 
production (Hart et al., 1989). 
 
When the effects of the selective COX-1 inhibitor SC-560 were investigated, very similar 
results were obtained. An enhancing effect of the LPS-induced gene expression was observed 
for the same genes except TNF-α as the COX-1 inhibitor had no effect on the gene expression 
of TNF-α. 
 
A trend for increased expression of MCP-1 mRNA was observed after addition of the 
selective COX-1 inhibitor as it was for aspirin. When the COX-2 inhibitor was used it did not 
seem to consistently affect the MCP-1 expression. MCP-1 is mainly expressed by 
macrophages in response to cytokines, such as TNF-α and IL-1β, and our results indicate that 
inhibition of platelet COX-1 leads to an increase in MCP-1 expression, whereas this is not the 
case when the inducible COX-2 activity is inhibited. It is difficult to speculate about the 
underlying mechanism for this observation. 
 
Inhibition of mPGES-1 expression and selective mPGES-1 inhibition. When the selective 
mPGES-1 inhibitor MF63 is added to freshly collected blood prior to stimulation with LPS, a 
selective inhibition of the production of PGE2 (with an IC50 of 1.3 μM) and no concomitant 
TxB2 inhibition were observed (Côté et al., 2007). The IC50 concentration is within the 
concentration range used in our study. With the addition of selective mPGES-1 inhibitor prior 
to LPS-stimulation, TF activity was dose-dependently increased. The effects on mRNA 
expression of the investigated proinflammatory genes were less pronounced and not 
significant for any of the genes. The mPGES-1 is inducible by various inflammatory stimuli 
and is primarily coupled to COX-2 (Murakami et al., 2003). Furthermore, it is up-regulated in 





Since we did not measure the direct effects on the production of the specific prostanoids (e.g. 
TxA2 and PGE2) in this study, we are not able to tell whether the addition of mPGES-1/ COX-
2 inhibitor might have inhibited the generation of both thromboxanes and PGE2.  
 
Dual COX-2/ 5-LOX inhibitor. To compare the results of the COX and prostaglandin E 
synthase inhibitors with the effects of inhibition of leukotrienes biosynthesis, we included a 
dual COX-2/ 5-LOX inhibitor in the study. However, as it did not significantly affect the 
LPS-induced TF activity, we did not include this inhibitor in the mRNA expression analysis. 
Yet, it was evident from the TF activity measurements that this inhibitor followed a different 
pattern compared to the other inhibitors since there was a trend for reduced TF-activity after 
treatment with the dual inhibitor. In LPS stimulated blood, the COX-2/ 5-LOX inhibitor has 
previously been reported to inhibit the release of TNF-α, IL-1β and IL-8, measured by ELISA. 
The IC50s for the inhibition of those cytokines were 33 μM, 11 μM and 6.7 μM, respectively 
(Hartman et al., 1995). Due to the solubility of the inhibitor, the highest dose used in our 
studies was 10 μM. This should be sufficient to significantly inhibit the production of TxA2. 
 
5.3. Leukocyte-platelet interactions measured by flow cytometry 
Platelet activation can be measured by the quantification of platelet-monocyte aggregates or 
heteroconjugates. It has recently been suggested that platelet-monocyte aggregates is a more 
robust indicator of in vivo platelet activation than platelet-leukocyte aggregates (Michelson et 
al., 2001). To compare the binding of platelets to monocytes and granulocytes, the effect of 
LPS and LPS+PAF in combination to stimulate platelets and leukocytes, measured as 
heteroconjugate formation, were examined. Most of the platelets were conjugated to the 
monocytes at all induction states of the blood, and especially after LPS+PAF stimulation. 
PAF is a relatively potent platelet inducer but also stimulate certain activation signals in 
leukocytes. After LPS stimulation alone, we hardly detected any CD42a, platelet marker, in 
the granulocyte window (Figure 22). The amount of platelets detected in the granulocyte 
window was much lower as compared to the situation in the monocyte window. It is further 
observed a great interindividual response to stimuli (monocyte population), which can also be 
explained by high responders and low responders (very low response to a stimulating agent). 
However, the relatively low amount of platelet binding to granulocytes compared to 
monocytes, suggest that platelets binding to granulocytes may require stronger stimulation or 
stimulation of a platelet-specific or granulocyte-specific activator. 
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As expected, LPS stimulation markedly increased specific surface markers of the granulocyte- 
and monocyte population (Figure 21). However, when whole blood stimulation with LPS and 
PAF in combination, a slightly reduction was seen in monocyte population compared to LPS 
alone. This effect was earlier observed in various cytokines expression when whole blood was 
stimulated with both LPS and different doses of PAF. This indicates that PAF only has a 
limited effect when used as a pre-stimulus of LPS-induced expression of proinflammatory 
mediators and molecules in whole blood. 
 
Granulocytes generate PAF, which interact with- and activate platelets, when blood is 
exposed to LPS (O'Flaherty & Wykle, 1983). Thus the small amount of detected platelets 
population may also caused by the activated granulocytes. For the granulocyte population, a 
small increase was observed when samples were stimulated with LPS and PAF. This might 
indicates that granulocytes release PAF (and granular enzymes), and PAF acts both as an 
autocrine activator, thus amplifying the granulocytes activation, but also as a paracrine which 
stimulate platelets and monocytes.  
 
The clear increase in the number of CD42a positive events in the monocyte gate is observed 
for samples stimulated with both LPS and PAF (Figure 22), which is indicative of platelet-
monocyte conjugates, thereby confirms the ability of PAF to enhance the LPS-inducing effect 
in stimulating platelet. Furthermore, our results confirm that PAF activates platelets and 
monocytes and stimulates platelet-monocyte interactions, without affecting the granulocytes 
to the same degree. This was demonstrated by Groscurth et al. using PAF as a single stimulus 
to whole citrated blood (Groscurth et al., 1988). They observed morphological changes in 
both monocytes and granulocytes, yet only monocytes came into close contact with platelets 
and platelet aggregates (Groscurth et al., 1988). As for the TF activity and mRNA expression 
studies, cell-cell interactions displayed a great interindividual response to the stimuli, which 
can also be explained by high responders and low responders phenomenon reported by 
Groscurth et al. 
 
As known, platelet-leukocyte aggregates or conjugates are mainly formed via platelet-
expressed P-selectin and its receptors PSGL-1 and CD15, and via fibrinogen bridging 
between glycoprotein IIb/ IIIa and CD11b/ CD18 (Lehr et al., 1994). P-selectin is expressed 
only on the surface of activated platelets, while PSGL-1 and CD15 are constitutively 
expressed on leukocytes. In our experiments, we observed a totally different situation for the 
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platelet granule protein P-selectin. Upon platelet stimulation, the platelets release their granule 
content. As demonstrated, P-selectin associates with platelets, granulocytes and monocytes, 
and almost equally distributed (Figure 23 and 25). CD42a which is a constitutively expressed 
platelet surface receptor known to be shedded from the platelet surface under certain 
conditions. In our study, the vast majority of the CD42a remained in the platelet window and 
not associated with granulocytes, whereas a certain part of the CD42a was detected in the 
monocyte and platelet windows but probably still attached to the platelet surface (Figure 24). 
 
Note, that the fluorescence signals detected for CD62P in our studies were quite low (Figure 
23), which may indicate that the monoclonal antibody did not work optimally. Due to the 
limited amount of time, we did not have the possibility to confirm the results using a different 




 Optimal incubation time for LPS stimulation was considered to be between 1.5 h and  
2 h. 
 LPS-stimulation of whole blood, as compared to saline controls, significantly 
increased the monocyte TF activity and cytokine mRNA expressions levels. 
 Aspirin was observed to enhance the LPS-induced TF activity in monocytes and the 
proinflammatory cytokine gene expressions. 
 As for aspirin, the COX-1 inhibitor SC-560, seemed to enhance the LPS-induced 
monocyte TF activity. The gene expression of proinflammatory cytokines was also 
increased. 
 The selective COX-2 inhibitor CAY10404 enhanced the LPS-induced gene expression 
of IL-8, IL-1β and MCP-1 as wells as the monocyte TF activity. The TF and TNF-α 
mRNA expression were not affected by the inhibitor. At the highest concentration of 
CAY10404, it did not enhance any of the genes, on the contrary a non-significantly 
reduction was observed for most genes.  
 The prostaglandin synthesis inhibitor CAY10526 was observed to have a biphasic 
effect in enhancing the monocyte TF activity, paralleled by an enhancing effect of the 
gene expression for all the proinflammatory cytokines. 
 The selective mPGES-1 inhibitor, MF63, showed a dose-related enhancing effect of 
monocyte TF activity. The effects of MF63 on the mRNA expression of the cytokines 
were general low and not significant; however, there was a trend for an enhancing 
effect on the LPS-induced gene expression for all the genes, except TF. 
 LPS-stimulation of whole blood significantly increased the respective markers of both 
the granulocyte- and monocyte populations. 
 Platelet was observed to interact and bind easily to monocyte, whereas platelet binding 






7. FUTURE PERSPECTIVES 
This thesis was performed under a very limited amount of time; hence a lot of the links and 
necessary experiments to complete the project are still missing. First of all, we were unable to 
tell whether the addition of the various inhibitors of the prostanoid biosynthesis actually 
inhibited the production of PGE2 and TxB2, therefore a quantification of these eicosanoids 
should be carried out, for example using ELISA. Furthermore, we probably should address 
the expression levels of the enzymes under investigation, COX-1, COX-2, mPGES and 
possibly also the cytosolic PGE synthase, in whole blood.  
 
The current research could be improved by using more parallels. By using more test persons, 
trends probably would become statistically significant, especially for MCP-1 gene expression. 
As it is great interindividual variations, the deletion of one subject could change the output of 
the result. Blood cells are observed to behave differently, depending on the type of 
anticoagulant used. It would be interesting to perform these experiments with different 
anticoagulants. 
 
Optimally, we might investigate the high responder phenomenon and perform the experiments 
with a larger group of individuals and group them according to their response towards LPS. 
However, further studies on longer term expression (also analyze at 4 and 8 h) should be 
performed in order to gain a better understanding of the effect on responses to a stimulating 
agent. This is important as it has been reported that the prostanoid biosynthesis/ release is a 
very time dependent process, in addition to the fact that the cytokines MCP-1 and IL-8 are 
optimally expressed later than 2 h. 
 
Moreover, in the flow cytometric analysis we need to address the link between the prostanoids 
and cell-cell interactions by performing experiments using flow cytometry on samples treated 
with the COX-1, COX-2 and mPGES inhibitors. Also in flow cytometric analysis 
anticoagulant test could be performed, as it has been shown that anticoagulant type has a 
marked effect on platelet-monocyte aggregate levels.  Fragmin is known as a very effective 
inhibitor of platelet activation, and the use of citrate may result in quite different results. 
Finally, in future work a different batch of the CD62P antibody should be used to be sure that 
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Appendices 
APPENDIX 1 – Primers and probes concentrations for real-time PCR analysis 
Calculation of primers and probes concentrations used in real-time PCR analysis. 
Gene: cyclophilin A 
Both primers had a stock concentrations of 200 μM. This concentration was diluted twenty 
times, by adding 380 μL dH2O to 20 μL of stock solution. The new concentration was then 10 
μM. For 1 reaction, 0.4 μL of primer solution was used (from earlier knowledge). Thus the 
concentration was found out by following equation: 
 
10000 nM * 0.4 μL = X nM * 20 μL 
      200 nM   = X 
 
Probe stock concentration was 100 μM. This was further diluted twenty times, which gave a 
new concentration of 5 μM. From earlier experience, 0.8 μL was used for each reaction. The 
probe concentration was found out: 
 
5000 nM * 0.8 μL = X nM * 20 μL 
                 200 nM = X 
 
Concentrations for the rest of the genes used in this work were found out in similar way. 
Table A-1 below shows the amount of primers and probes used in this work. 
 
Table A-1. Primers and probes concentrations. 
Reagents Cyclophilin A TF TNF-α 
 á x80 á x80 á x80 
2X mastermix 10 800 10 800 10 800 
Forward primer 0.4  32 (200 nM) 0.4 32 (200 nM) 0.8 64 (400 nM) 
Reverse primer 0.4  32 (200 nM) 0.4 32 (200 nM) 0.8 64 (400 nM) 
Probe 0.8 64 (200 nM) 0.4 32 (100 nM) 0.8 64 (200 nM) 
dH2O 4.4 352 4.8 384 3.6 288 
 16 1280 16 1280 16 1280 
 
 
Reagents Interleukin 1β Interleukin 8 MCP – 1 
 á x80 á x80 á x80 
2X mastermix 10 800 10 800 10 800 
Forward primer 0.8  64 (400 nM) 0.8 64 (400 nM) 0.8 64 (400 nM) 
Reverse primer 0.8  64 (400 nM) 0.8 64 (400 nM) 0.8 64 (400 nM) 
Probe 0.2 16 (100 nM)2  0.8 64 (200 nM) 0.2 16 (100 nM)3
dH2O 4.2 336 3.6 288 4.2 336 
 16 1280 16 1280 16 1280 
 
 
                                                 
2 Probe #78, Roche Applied Science Universal Probe 
3 Probe #40, Roche Applied Science Universal Probe 
 II
Appendices 
APPENDIX 2 – Real-time PCR efficiency  
 
In order to quantify the obtained results, standard curves were made for each of the genes. 
Relative gene expression was calculated based on the primer efficiency, Ct values of unknown 
sample and the respective sample of the reference gene. 
 




Genes Slope Efficiency R2 Y-intercept Ct 
Cyclo A -3.466 0.9432 0.9975 35 
TF -3.3513 0.9879 0.9954 38 
TNF-α -3.4068 0.9658 0.9972 33 
IL-1β -3.3470 0.9896 0.9956 32 





Genes Slope Efficiency R2 Y-intercept Ct 
Cyclo A -3.3098 1.0051 0.9942 36 
TF -3.4170 0.9618 0.9922 38 
TNF-α -3.2830 1.0165 0.9982 33 
IL-1β -3.2877 1.0145 0.9972 32 





Genes Slope Efficiency R2 Y-intercept Ct 
Cyclo A -3.4119 0.9634 0.9991 34 
TF -3.3163 1.0023 0.9981 38 
TNF-α -3.4303 0.9567 0.9995 33 
IL-1β -3.3591 0.9847 0.9972 30 
IL-8 -3.4218 0.9599 0.9988 30 





Genes Slope Efficiency R2 Y-intercept Ct 
Cyclo A -3.4792 0.9383 0.9990 36 
TF -3.4244 0.9589 0.9972 36 
TNF-α -3.4030 0.9672 0.9990 33 
IL-1β -3.2642 1.0247 0.9969 30 






Genes Slope Efficiency R2 Y-intercept Ct 
Cyclo A -3.4587 0.9459 0.9972 36 
TF -3.4679 0.9425 0.9950 36 
TNF-α -3.3038 1.0076 0.9987 32 
IL-1β -3.3023 1.0083 0.9982 31 





Genes Slope Efficiency R2 Y-intercept Ct 
Cyclo A -3.4521 0.9484 0.9980 35 
TF -3.3327 0.9955 0.9934 40 
TNF-α -3.3313 0.9961 0.9980 33 
IL-1β -3.4484 0.9498 0.9996 30 
IL-8 -3.4524 0.9483 0.9991 30 
MCP-1 -3.3520 0.9876 0.9969 40 
 
 
 
 
 IV
